~~10/513699~~ 10/524,123 search b4 election

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS 24	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

<12/04/2007> Erich Leese

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:01:21 ON 27 APR 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:01:37 ON 27 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2007 HIGHEST RN 933069-51-3
DICTIONARY FILE UPDATES: 26 APR 2007 HIGHEST RN 933069-51-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10524123.str

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 15:02:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4536 TO ITERATE

44.1% PROCESSED 2000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 86681 TO 94759
PROJECTED ANSWERS: 4 TO 361

L2 4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:02:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 90049 TO ITERATE

<12/04/2007> Erich Leese

100.0% PROCESSED 90049 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.02

L3 33 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 15:02:13 ON 27 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Apr 2007 VOL 146 ISS 19
FILE LAST UPDATED: 26 Apr 2007 (20070426/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 16 L3

=> s l4 and py<2003
22870615 PY<2003
L5 16 L4 AND PY<2003

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:385709 CAPLUS
DOCUMENT NUMBER: 137:201371
TITLE: Novel ene-like cycloisomerization reaction of nitrile oxides with a tethered allyltrimethylsilyl group
AUTHOR(S): Ishikawa, Teruhiko; Urano, Jin; Ikeda, Shushiro; Kobayashi, Yasuhiro; Saito, Seiki
CORPORATE SOURCE: Department of Bioscience and Biotechnology, Faculty of Engineering, Okayama University, Okayama, 700-8530, Japan
SOURCE: Angewandte Chemie, International Edition (2002), 41(9), 1586-1588
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:201371
GI



I



II

AB Rather than the expected [3+2] cycloaddn., a novel ene-like cycloisomerization occurs on deprotonation of allyltrimethylsilyl-oxime compds. when the β-sp2 carbon atom of the allyltrimethylsilyl moiety is tethered to the oxime unit. The resulting nitrile oxide functional group serves as an enophile, and the final cyclized product still has two functional groups suitable for further manipulations. Thus, ene-like cycloisomerization of allyltrimethylsilyl-oxime I with NaOCl in CH2Cl2 gave 82% cyclized product II.
IT 452306-05-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 452306-05-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[(trimethylsilyl)methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:191138 CAPLUS
DOCUMENT NUMBER: 128:257364
TITLE: Intramolecular cycloaddition of nitrones and nitrile oxides with sulfur-substituted dienes and its synthetic applications
AUTHOR(S): Chou, Shang-Shing P.; Yu, Yu-Ju
CORPORATE SOURCE: Dep. Chem., Fu Jen Catholic Univ., Taichung, 242, Peop. Rep. China
SOURCE: Journal of the Chinese Chemical Society (Taipei) (1998), 45(1), 163-173
CODEN: JCCTAC; ISSN: 0009-4536
PUBLISHER: Chinese Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:257364

AB A series of sulfur-substituted dienyl nitrones and oximes were conveniently prepared from the 3-sulfolene precursors. Regiospecific intramol. 1,3-dipolar cycloaddns. of nitrones and nitrile oxides with sulfur-substituted dienes have been efficiently carried out from the suitable 3-sulfolene precursors. The stereochem. of the cycloaddn. of nitrones depends on the structure of the substituent (sulfide or sulfone) on the diene as well as on the chain length connecting the diene and nitrone. The fused bicyclic products obtained from these reactions have been converted to some interesting heterocyclic compds. which have the useful structure of vinyl sulfide or sulfone.

IT 205110-63-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(intramol. cycloaddn. of nitrones and nitrile oxides with sulfur-substituted dienes)

RN 205110-63-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylthio)ethenyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:431584 CAPLUS
DOCUMENT NUMBER: 127:149098
TITLE: A convenient synthesis of 3- and 3,4-substituted 4,5-dihydroisoxazole-5-acetic acids
AUTHOR(S): Eichinger, Karl; Wokurek, Michael; Zauner, Bernd; Rostami, Mohammad Reza
CORPORATE SOURCE: Institute of Organic Chemistry, Vienna University of Technology, Vienna, A-1060, Austria
SOURCE: Synthetic Communications (1997), 27(16), 2733-2742
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:149098
GI



I

AB The 4,5-dihydroisoxazole-5-acetic acids I [R1 = Ph, Me, 4-ClC6H4, 4-MeOC6H4, 4-PhC6H4, R2 = H, SPh, OPh, 4-ClC6H4; R1R2 = (CH2)4, (CH2)10, 1,2,3,4-tetrahydronaphth-1,2-diyl] were prepared from the ketoximes R1C(CH2R2):NOH, 2,2-dimethyl-5-methoxymethylene-1,3-dioxan-4,6-dione and butyllithium in yields from 35 to 79 %.

IT 193267-49-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isoxazoleacetic acids)

RN 193267-49-1 CAPLUS
CN 2,1-Benzisoxazole-3-acetic acid, 3,3a,4,5,6,7-hexahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:390560 CAPLUS
DOCUMENT NUMBER: 125:168364
TITLE: A highly convergent enantioselective total synthesis of marine natural product, furanoterpene
AUTHOR(S): Bando, Toshikazu; Shishido, Kozo
CORPORATE SOURCE: Inst. for Medicinal Resources, Univ. Tokushima, Sho,

770, Japan
SOURCE: Chemical Communications (Cambridge) (1996), (11), 1357-1358
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:168364
GI



I

AB The enantioselective total convergent synthesis of marine furanoterpene (I) is achieved and the absolute configuration of the only existing quaternary stereogenic center is found to be S.
IT 180333-99-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(a highly convergent enantioselective total synthesis of furanoterpene)
RN 180333-99-7 CAPLUS
CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7-[(methoxymethoxy)methyl]-7-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:29561 CAPLUS
DOCUMENT NUMBER: 124:232296
TITLE: Effect of the α-alkyl substituent of conjugated nitroolefins on the formation of cyclic nitronic esters vs. nitrocyclopropanes in their reaction with sulfur ylides
AUTHOR(S): Kumaran, G.; Kulkarni, Gurunath H.
CORPORATE SOURCE: Div. Org. Chem., Natl. Chem. Lab., Pune, 411008, India
SOURCE: Synthesis (1995), (12), 1545-8
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Thieme
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:232296
AB The formation of cyclic nitronic esters, isoxazoline N-oxides vs. nitrocyclopropanes in the reaction of conjugated nitroolefins with sulfur ylides depends on the presence of an α-alkyl substituent in the

conjugated nitroolefins.
IT 174574-89-1P 174574-92-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(effect of alkyl substituent on cyclic nitronate and nitrocyclopropane formation in cycloaddn. of conjugated nitroolefins with sulfur ylides)
RN 174574-89-1 CAPLUS
CN 2,1-Benzisoxazole-3-carboxylic acid, 3,3a,4,5,6,7-hexahydro-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 174574-92-6 CAPLUS
CN Methanone, (3,3a,4,5,6,7-hexahydro-1-oxido-2,1-benzisoxazol-3-yl)phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:560649 CAPLUS
DOCUMENT NUMBER: 119:160649
TITLE: Preparation of secosteroids having vitamin D activities.
INVENTOR(S): Sotojima, Fukuo
PATENT ASSIGNEE(S): Juki Gosei Yakuhin Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05058991	A	19930309	JP 1991-254255	19910906 <--
PRIORITY APPLN. INFO.:			JP 1991-254255	19910906

OTHER SOURCE(S): CASREACT 119:160649; MARPAT 119:160649

GI



AB The title compds. [R1, R2 = H, protecting group] are prepared in many steps from a heptenetriol derivative, e.g., HO-CH2-CH:CH-CH2-CHQ-CH2-CH2-O-Q1 [Q = tert-butyldiphenylsilyl, Q1 = p-methoxyphenyl]. E.g., the (nitrooctenylidene)cyclohexane derivative II (multistep preparation given) was cyclized in benzene contg Et3N and Ph isocyanate to give III diastereomers, one of which in H2O containing B(OMe)3 was treated with Raney Ni in EtOH to give I [R1 = R2 = Q1].

IT 149741-09-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring cleavage of)

RN 149741-09-3 CAPLUS

CN 2,1-Benzisoxazole, 3-(cyclohexylidenemethyl)-7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,3a,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:234262 CAPLUS

DOCUMENT NUMBER: 118:234262

TITLE: A general synthetic route to fused furans. Total synthesis of (+)-pallescensin A

AUTHOR(S): Shishido, Kozo; Umimoto, Koji; Ouchi, Mikiko; Irie, Osamu; Omodani, Tomoki; Takata, Takeshi; Shibuya, Masayuki

CORPORATE SOURCE: Inst. Med. Resour., Univ. Tokushima, Tokushima, 770, Japan

SOURCE: Journal of Chemical Research, Synopses (1993

), (2), 58-9
CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A general and facile synthetic route to fused furans has been developed. The key step of the transformation involves the intramol. [3+2] dipolar cycloaddn. reaction of nitrile oxides which were generated in situ from the corresponding oxime acetates. Reductive hydrolysis of the resulting dihydroisoxazoles followed by alkaline hydrolysis provided β,γ-dihydroxy ketones which were immediately treated with a catalytic amount of p-toluenesulfonic acid to afford the fused furans I (R = Me, R1 = H; R = H, R1 = Me). Alternatively, the alcs., derived by hydrolysis of the dihydroisoxazoles, were submitted to a sequential reductive hydrolysis and acid treatment to provide I. Addnl. dihydroisoxazole alcs., prepared from com. available phthalide, were similarly treated to give the tricyclic fused furans II (R2 = H, Me, R3 = Me; R2 = Me, R3 = H) in reasonable yields. The methodol. developed here has been successfully applied to a total synthesis of (+)-pallescensin A (III) starting with (+)-Wieland-Miescher ketone.

IT 147378-09-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reductive hydrolysis of)

RN 147378-09-4 CAPLUS

CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7,7-dimethyl-, acetate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 147378-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, deacetylation, and cyclization of)

RN 147378-18-5 CAPLUS

CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7,7-dimethyl-, cis-

(9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:570854 CAPLUS
DOCUMENT NUMBER: 117:170854
TITLE: Preparation of (dihydroxyethyl)cyclohexanone derivatives as intermediates for ring A fragments of compounds having vitamin D-like activity
INVENTOR(S): Sotojima, Fukuo
PATENT ASSIGNEE(S): Yuki Gosei Yakuhin Kogyo K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04082856	A	19920316	JP 1990-194847	19900725 <--
PRIORITY APPLN. INFO.:			JP 1990-194847	19900725

OTHER SOURCE(S): CASREACT 117:170854; MARPAT 117:170854
GI



I

II



IV



V

AB The title compds. I (R1-R4 = H, OH-protecting group) are prepared from CH2:CHCH2CH2OR5 (R5 = H, OH-protecting group) via intermediates such as epoxides (II), alkynes R3OCH2C.tplbond.CCH2CH(OR1)CH2CH2OR5 (III; R1, R3, R5 = same as above), olefins [IV; R = CH2OR5, CHO, CH(OR2)CH2NO2; R1, R2, R3, R5 = same as above], and isoxazole derivs. (V; R1-R3 = same as above). Thus, ring-opening addition reaction of II (R5 = CH2C6H4OMe-p)(preparation given) with HC.tplbond.CCH2OTHP (THP = terahydropyranyl) in the presence of BF3.Et2O after metalation with BuLi, conversion of the resulting III (R1 = H, R3 = THP, R5 = CH2C6H4OMe-p) into IV (R = CHO, R1 = SiPh2Bu-tert, R3 = THP) via silylation, debenzylation, partial hydrogenation over Lindlar catalyst, and oxidation with pyridinium chlorochromate, and addition reaction of the aldehyde with MeNO2 in the presence of KF and 18-crown-6 gave IV [R = CH(OH)CH2NO2, R1 = SiPh2Bu-tert, R3 = THP]. Silylation of the last with CF3SO3SiMe2Bu-tert in the presence of 2,6-lutidine, cyclization of the resulting IV [R = CH(OSiMe2Bu-tert)CH2NO2, R1 = SiPh2Bu-tert, R3 = THP] by treatment with Et3N and PhCNO, and hydrogenation of the resulting V (R1, R3 = same as above; R2 = SiMe2Bu-tert) over Raney nickel in the presence of H2O gave I (R = SiPh2Bu-tert, R2 = SiMe2Bu-tert, R3 = THP, R4 = H).

IT 142860-74-0P 142860-82-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in preparation of cyclohexanone derivative as intermediate for ring A fragment of vitamin D analog)

RN 142860-74-0 CAPLUS
CN 2,1-Benzisoxazole, 7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,3a,4,5,6,7-hexahydro-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 142860-82-0 CAPLUS
CN 2,1-Benzisoxazole, 5,7-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,3a,4,5,6,7-hexahydro-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:458998 CAPLUS
DOCUMENT NUMBER: 113:58998
TITLE: Reaction of Cα,O-dilithiooximes with functionalized carbonyl compounds. Part 2. Reaction with α-chloroketones and α,β-unsaturated aldehydes and ketones
AUTHOR(S): Jarrar, Adil A.; Hussein, Ahmad Q.; Madi, Ahmad S.
CORPORATE SOURCE: Fac. Sci., Univ. Jordan, Amman, Jordan
SOURCE: Journal of Heterocyclic Chemistry (1990), 27(2), 275-8
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:58998
GI



II

IV

AB Reaction of LiON:CRCHR1Li (I; R = Ph, 4-MeC6H4; R1 = H) with 4-R2C6H4COCH2Cl (R2 = H, Me) afforded (hydroxymethyl)isoxazoline II in 62-77% yield. Similar reaction of I [R = Ph, 4-MeC6H4, 4-BrC6H4, R1 = H; RR1 = (CH2)4] with R3COCH:CR3R4 (R3 = H, Me; R4 = H, Me, Ph) gave HON:CRCHR1CR3(OH)CH:CR3R4 (III) in 63-80% yield. Treatment of III with P2O5 gave vinylisoxazolines IV.
IT 128094-36-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 128094-36-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(2-phenylethenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:477887 CAPLUS
DOCUMENT NUMBER: 111:77887
TITLE: Stepwise intramolecular cycloaddition of nitrile oxide equivalents derived from the Lewis acid-promoted reaction of 1-nitroalkadienes and allylic stannanes
AUTHOR(S): Uno, Hidemitsu; Goto, Kenichi; Watanabe, Noriko; Suzuki, Hitomi
CORPORATE SOURCE: Fac. Sci., Ehime Univ., Matsuyama, 790, Japan
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1989), (2), 289-95
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:77887
AB The Lewis acid-promoted reaction of 1-nitroalka-1,5-(or 1,6-)dienes with allylic stannanes has been studied. In the presence of TiCl4, 1-nitrohexa-1,5-diene reacted smoothly with allyltrimethylstannane to give a diastereoisomeric mixture of 6-allyl-3a,4,5,6-tetrahydro-3H-cyclopent[c]isoxazoles, while the reaction using AlCl3 as catalyst led to an allylated cyclohexanone oxime derivative in good yield. Similar reaction of 1-nitrohepta-1,6-diene, however, gave a bicyclic dihydroisoxazole irresp. of the Lewis acids employed. In the latter case, nitrile oxide equivs. derived from 1-nitroalka-1,6-dienes underwent a stepwise cycloaddn. as shown by the lack of stereospecificity in the reactions of (1E,6Z)-1-nitro-7-phenylhepta-1,6-diene and (1E,6Z)-1-nitrooocta-1,6-diene.
IT 121948-65-0P 122045-15-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectra of)
RN 121948-65-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-7-(2-propenyl)-, (3α,3aα,7β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 122045-15-2 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-7-(2-propenyl)-, (3α,3aβ,7α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:21762 CAPLUS
DOCUMENT NUMBER: 108:21762
TITLE: Stereoselective intramolecular nitrile oxide cycloaddition to chiral allyl ethers
AUTHOR(S): Annunziata, Rita; Cinquini, Mauro; Cozzi, Franco; Raimondi, Laura
CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milano, Milan, I-20133, Italy
SOURCE: Journal of the Chemical Society, Chemical Communications (1987), (8), 529-30
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:21762
GI



AB Intramol. nitrile oxide cycloaddn. reactions on (Z)- and (E)-chiral allyl ethers occur with poor to good stereoselectivity (diastereoisomeric ratios up to 86:14), which depends on the double bond configuration as well as on steric and stereoelectronic effects. Thus, PhCH2OCHMeCH:CH(CH2)4CH:NOH was treated with NaOCl to give isoxazole derivs. I and II.
IT 109960-80-7P 109960-81-8P 110013-28-0P
110013-29-1P 110013-30-4P 110013-31-5P
110013-32-6P 110013-33-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 109960-80-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109960-81-8 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-28-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-29-1 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-30-4 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-31-5 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-32-6 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-33-7 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:575238 CAPLUS
DOCUMENT NUMBER: 107:175238
TITLE: Stereoselectivity of intramolecular nitrile oxide cycloadditions to Z and E chiral alkenes
AUTHOR(S): Annunziata, Rita; Cinquini, Mauro; Cozzi, Franco; Gennari, Cesare; Raimondi, Laura
CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milano, Milan, I-20133, Italy
SOURCE: Journal of Organic Chemistry (1987), 52(21), 4674-81
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:175238
AB Treatment of (E)- and (Z)-RCHR1CH:CHCH2CH2(CH2)nCH:NOH [R = PhCH2O, PhCH2OCH2, Me2CH; R1 = Me, PhCH2O; RR1 = O(CH2)5OCH2] with NaOCl gave nitrile oxides, which were trapped by intramol. cycloaddn. to give isoxazoline diastereoisomer mixts. The anal. of the products was combined with MM2 calcns. on the transition structures. With the (E)-alkenes, electronic factors govern the stereoselectivity; with the (Z)-alkenes steric factors are more important.
IT 109960-99-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 109960-99-8 CAPLUS
CN 1,2-Ethanediol, 1-(3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)-, 2-(4-methylbenzenesulfonate), [3S-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)



IT 109960-98-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)
RN 109960-98-7 CAPLUS
CN 1,2-Ethanediol, 1-(3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)-, [3S-[3α(S*),4β]]- (9CI) (CA INDEX NAME)



IT 109960-80-7P 109960-81-8P 109960-83-0P
110013-28-0P 110013-29-1P 110013-30-4P
110013-31-5P 110013-32-6P 110013-33-7P
110013-37-1P 110013-38-2P 110013-39-3P
110013-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 109960-80-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109960-81-8 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109960-83-0 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-,

[3α(S*),3aβ]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110013-28-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-29-1 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-30-4 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-31-5 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-32-6 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-33-7 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-37-1 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(R*),3aβ]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110013-38-2 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(S*),4α]- (9CI) (CA INDEX NAME)



RN 110013-39-3 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(R*),3aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110013-46-2 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(S*),4β]]- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1985:560616 CAPLUS
DOCUMENT NUMBER: 103:160616
TITLE: Oxidative fragmentation of β-stannyl oximes: stereospecific formation of unsaturated nitrile oxides
AUTHOR(S): Nishiyama, Hisao; Arai, Hiroyuki; Ohki, Takashi; Itoh, Kenji
CORPORATE SOURCE: Sch. Mater. Sci., Toyohashi Univ. Technol., Tempaku, 440, Japan
SOURCE: Journal of the American Chemical Society (1985), 107(18), 5310-12
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:160616
GI



AB A new stereospecific oxidative-fragmentation was found by treatment of cyclic (E)-β-tributylstannyl oximes (I, R = H, R1 = Me; R = Me, R1 = H) with lead tetraacetate to give the unsatd. nitrile oxides II which gave in one-pot the Δ2-isoxazolines III, resp., via intramol. 1,3-dipolar cycloaddn. Dramatic conversion of their cyclic skeleton was completely controlled by the stannyl function. It is noteworthy that the linear (Z)-β-stannyl oximes IV (R1 = Ph, Me3C) gave directly the cyclization products V. Stereoselectivity of the fragmentation of several linear

oximes was also demonstrated. Stereocontrolled homolytic process via iminoxyl radicals, generated by oxidation of the oximes, could be postulated.
IT 97782-43-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 97782-43-9 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1983:505163 CAPLUS
DOCUMENT NUMBER: 99:105163
TITLE: Reduction of Δ2-isoxazolines. 3. Raney nickel catalyzed formation of β-hydroxy ketones
AUTHOR(S): Curran, Dennis P.
CORPORATE SOURCE: Dep. Chem., Univ. Pittsburgh, Pittsburgh, PA, 15260, USA
SOURCE: Journal of the American Chemical Society (1983), 105(18), 5826-33
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 99:105163
GI



AB Olefins underwent [2 + 3] dipolar cycloaddn. with nitrile oxides to give 2-isoxazolines, which were transformed to β-hydroxy ketones with Raney Ni catalyst, boric acid, 5:1 MeOH-H2O, and H. This cycloaddn.-reduction sequence allowed diastereospecific formation of threo and erythro products. Thus cycloaddn. of RCNO (R = Me, Ph) with trans-2-butene gave isoxazolines trans-I, which were reduced to threo-RCOCHMeCHMeOH (threo-II), while cis-2-butene gave cis-I, and erythro-II upon reduction
IT 82150-04-7P 82150-10-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of, β-hydroxyketones by)
RN 82150-04-7 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 82150-10-5 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1982:509909 CAPLUS
DOCUMENT NUMBER: 97:109909
TITLE: Reduction of Δ2-isoxazolines: a conceptually different approach to the formation of aldol adducts
AUTHOR(S): Curran, Dennis P.
CORPORATE SOURCE: Dep. Chem., Univ. Pittsburgh, Pittsburgh, PA, 15260, USA
SOURCE: Journal of the American Chemical Society (1982), 104(14), 4024-6
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The isoxazolines I [R1 = H, Me, Pr; R2 = H, Me; R3 = Me, Pr, Bu, Ph; R1R2 = (CH2)4, (CH2)3, R3 = H], prepared by nitrile oxide-olefin cycloaddn., underwent reduction by H2 in presence of Raney Ni to give the aldol adducts II. The cycloalkaisoxazoline III (n = 1, 2; R3 = H, Me, Ph; R4 = H, Me, Ph, CH2OAc) were similarly reduced to give the aldol adducts IV.
IT 82150-04-7 82150-10-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(catalytic reduction of)
RN 82150-04-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 82150-10-5 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1972:488371 CAPLUS
DOCUMENT NUMBER: 77:88371
TITLE: Reaction of keto-stabilized sulfonium and arsonium ylides with α-chlorooximes. New synthesis of Δ2-isoxazolines
AUTHOR(S): Bravo, P.; Gaudiano, G.; Ponti, P. P.; Ticozzi, C.
CORPORATE SOURCE: Ist. Chim., Politec. Milano, Milan, Italy
SOURCE: Tetrahedron (1972), 28(14), 3845-54
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 77:88371
GI For diagram(s), see printed CA Issue.
AB The reaction of α-chloro oximes or the isomeric nitroso chlorides with keto-stabilized dimethylsulfonium or triphenylarsonium ylides gave trans-5-acyl-2-isoxazolines (I, e.g., R, R1 = Me, Ph, R2 = Bz). The NOCl adducts of Et propenyl ether and Et styryl ether on reaction with dimethylsulfonium phenacylide gave 3-substituted 5-benzoylisoxazoles. Dimethylsulfonium carbethoxymethylide (II) and 2-chloro-2-phenylacetone oxime gave Et β-acetylcinnamate oxime. II and 2-chlorocyclooctanone

oxime gave the thioether (III).
IT 37543-31-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37543-31-0 CAPLUS
CN Methanone, (3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)phenyl-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	88.68	260.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.48	-12.48

FILE 'REGISTRY' ENTERED AT 15:05:18 ON 27 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2007 HIGHEST RN 933069-51-3
DICTIONARY FILE UPDATES: 26 APR 2007 HIGHEST RN 933069-51-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10524123new.str

L6 STRUCTURE UPLOADED

=> d 16
L6 HAS NO ANSWERS
L6 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l6 full
FULL SEARCH INITIATED 15:05:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 90049 TO ITERATE

100.0% PROCESSED 90049 ITERATIONS 824 ANSWERS
SEARCH TIME: 00.00.01

L7 824 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	433.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.48

FILE 'CAPLUS' ENTERED AT 15:05:59 ON 27 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 27 Apr 2007 VOL 146 ISS 19
FILE LAST UPDATED: 26 Apr 2007 (20070426/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7 full
L8 34 L7

=> s l8 and py<2003
22870615 PY<2003
L9 22 L8 AND PY<2003

=> d ibib abs hitstr tot

L9 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:953007 CAPLUS
DOCUMENT NUMBER: 138:153469
TITLE: Synthesis, high-resolution NMR spectroscopic analysis, and single-crystal X-ray diffraction of isoxazoline tetracycles
AUTHOR(S): Fascio, Mirta L.; Alvarez-Larena, Angel; D'Accorso, Norma B.
CORPORATE SOURCE: Facultad de Ciencias Exactas y Naturales, Departamento de Quimica Organica, Centro de Investigaciones de Hidratos de Carbono (CIHIDECAR), Universidad de Buenos Aires, Buenos Aires, 1428, Argent.
SOURCE: Carbohydrate Research (2002), 337(24), 2419-2425
CODEN: CRBRAT; ISSN: 0008-6215
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:153469
GI



I



II

AB Three isoxazoline tetracycles I (R1 = H, R2 = Me; R1 = H, R2 = Ph; R1 = R2 = Me) were obtained enantiomerically pure by intramol. 1,3-dipolar cycloaddn. of mono-oxime α-D-glucofuranose derivs. II, derived from 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose. The characterization of the new compds. was performed by high-resolution 1H and 13C NMR spectroscopy. The relative configuration of the new chiral centers was determined by NOESY expts. and confirmed by single-crystal X-ray structural anal.

IT 495413-22-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis of isoxazoline tetracycles by intramol. 1,3-dipolar cycloaddn. of mono-oxime alkenyl-di-O-isopropylidene-α-D-glucofuranose derivs. and crystal structure)
RN 495413-22-4 CAPLUS
CN 3H-[1,3]Dioxolo[4',5']furo[2',3':5,6]pyrano[4,3-c]isoxazole, 3a,4,5a,5b,8a,9a-hexahydro-3,7,7-trimethyl-, (3R,3aR,5aS,5bR,8aR,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:658130 CAPLUS
DOCUMENT NUMBER: 137:201298
TITLE: Preparation of substituted isoxazolines as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Fernandez-Gadea, Francisco Javier; Alcazar-Vaca, Manuel Jesus; Cid-Nunez, Jose Maria; Pastor-Fernandez, Joaquin; Megens, Antonius Adrianus Hendrikus Petrus; Heylen, Godelieve Irma Christine Maria; Langlois, Xavier Jean Michel; Bakker, Margaretha Henrica Maria; Steckler, Thomas Horst Wolfgang
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066484	A1	20020829	WO 2002-EP1567	20020213 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437505	A1	20020829	CA 2002-2437505	20020213 <--
AU 2002244717	A1	20020904	AU 2002-244717	20020213 <--

EP 1368358	A1	20031210	EP 2002-712909		20020213
EP 1368358	B1	20060823			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EE 200300398	A	20031215	EE 2003-398		20020213
HU 200303270	A2	20040128	HU 2003-3270		20020213
CN 1492871	A	20040428	CN 2002-805243		20020213
NZ 526741	A	20040430	NZ 2002-526741		20020213
BR 2002007433	A	20040601	BR 2002-7433		20020213
JP 2004518748	T	20040624	JP 2002-565998		20020213
AT 337322	T	20060915	AT 2002-712909		20020213
TW 257392	B	20060701	TW 2002-91102853		20020220
BG 107984	A	20040930	BG 2003-107984		20030708
NO 2003003700	A	20031021	NO 2003-3700		20030820
ZA 2003006487	A	20041122	ZA 2003-6487		20030820
US 2004122037	A1	20040624	US 2003-468555		20030821
US 7169786	B2	20070130			
PRIORITY APPLN. INFO.:			EP 2001-200611	A	20010221
			EP 2001-201264	A	20010405
			WO 2002-EP1567	W	20020213

OTHER SOURCE(S): MARPAT 137:201298

GI



I



II



III

AB Title compds. I [wherein X = CH2, NR7, S or O; R7 = H, (un)substituted alkyl, Ph, Ph alkyl, etc.; R1 and R2 independently = H, OH, CN, halo, OSO2H, (un)substituted Ph, phenylalkyl, alkoxy, etc.; or R1 and R2 may be taken together to form a bivalent radical selected from -CH2CH2O-, -OCH2CH2-, -OCH2O-, -CH2OCH2- and -OCH2CH2O-; m = 1-4; Y = (un)substituted

piperidyl or piperazyl radical and R3 represents an (un)substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Y radical and which may contain one or more heteroatoms selected from the group of O, N and S], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine for treating anxiety disorders and disorders of body weight are disclosed. Thus, II was prepared in 60% yield by reaction of III with N-(3-phenyl-2-propenyl)-piperazine. III was prepared by substitution of Me 4-bromo-2-butenoate with 2-hydroxy-4,5-dimethoxybenzaldehyde with subsequent condensation with hydroxylamine, cyclization, reduction and sulfonation with methanesulfonyl chloride. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at the hα2A site (but often also at the hα2B and hα2C sites) and simultaneously at the 5-HT transporter site of more than 50% (pIC50) at a test concentration ranging between 10-6 M and 10-9 M in a concentration dependent manner. The invention also relates to novel combination of substituted isoxazolines derivs. having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

IT 452321-67-4P 452321-69-6P 452321-71-0P
452321-73-2P 452321-75-4P 452321-77-6P
452321-80-1P 452321-82-3P 452321-85-6P
452321-87-8P 452321-89-0P 452321-91-4P
452321-93-6P 452321-95-8P 452321-97-0P
452321-99-2P 452322-05-3P 452322-07-5P
452322-09-7P 452322-19-9P 452322-21-3P
452322-23-5P 452322-29-1P 452322-30-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452321-67-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-, methyl ester, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-69-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-71-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, methanesulfonate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-73-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7-hydroxy-8-methoxy-, α-methanesulfonate, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-77-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, methanesulfonate (ester), (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 452321-80-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, methanesulfonate (ester), (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 452321-82-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-85-6 CAPLUS
CN 2-Propanone, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-87-8 CAPLUS
CN Piperazine, 1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-[(3,4-dihydro-2-naphthalenyl)carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-89-0 CAPLUS
CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-,

bromide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-91-4 CAPLUS
CN Piperazine, 1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-(3-iodo-2-methyl-1-oxo-2-propenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452321-93-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-iodo-2-methyl-2-propenyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452321-95-8 CAPLUS
CN 1-Piperazineethanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-97-0 CAPLUS
CN 1,2-Propanediol, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-99-2 CAPLUS
CN 1-Piperazineacetaldehyde, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-05-3 CAPLUS
CN Isoxazolo[4,3-c]quinoline-3-carboxylic acid, 3,3a,4,5-tetrahydro-5-(trifluoroacetyl)-, methyl ester, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-07-5 CAPLUS
CN Isoxazolo[4,3-c]quinoline-3-methanol, 3,3a,4,5-tetrahydro-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-09-7 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-(chloromethyl)-3,3a,4,5-tetrahydro-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-19-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-21-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-23-5 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-29-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]amino]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-30-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-(4-piperidinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452322-32-6D, resin bound 452323-46-5D, resin bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452322-32-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



RN 452323-46-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(diphenylphosphino)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452313-32-5P 452313-68-7P 452313-71-2P
452313-80-3P 452313-82-5P 452316-78-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452313-32-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452313-68-7 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-80-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



●2 HCl

RN 452313-82-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



●2 HCl

RN 452316-78-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

IT 452313-59-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452313-59-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452313-36-9P 452313-40-5P 452313-43-8P
452313-46-1P 452313-50-7P 452313-54-1P
452313-56-3P 452313-61-0P 452313-65-4P
452313-74-5P 452313-77-8P 452313-85-8P
452313-88-1P 452313-91-6P 452313-93-8P
452313-98-3P 452314-01-1P 452314-05-5P
452314-08-8P 452314-11-3P 452314-14-6P
452314-16-8P 452314-18-0P 452314-20-4P
452314-23-7P 452314-26-0P 452314-29-3P
452314-31-7P 452314-34-0P 452314-37-3P
452314-40-8P 452314-43-1P 452314-46-4P
452314-49-7P 452314-52-2P 452314-55-5P
452314-57-7P 452314-60-2P 452314-62-4P
452314-65-7P 452314-68-0P 452314-71-5P
452314-74-8P 452314-77-1P 452314-80-6P
452314-83-9P 452314-86-2P 452314-89-5P
452314-92-0P 452314-95-3P 452314-98-6P
452315-01-4P 452315-04-7P 452315-07-0P

452315-10-5P 452315-13-8P 452315-16-1P
452315-19-4P 452315-22-9P 452315-24-1P
452315-27-4P 452315-30-9P 452315-33-2P
452315-36-5P 452315-38-7P 452315-40-1P
452315-42-3P 452315-44-5P 452315-46-7P
452315-48-9P 452315-51-4P 452315-52-5P
452315-55-8P 452315-58-1P 452315-61-6P
452315-63-8P 452315-66-1P 452315-70-7P
452315-73-0P 452315-76-3P 452315-79-6P
452315-82-1P 452315-85-4P 452315-87-6P
452315-90-1P 452315-92-3P 452315-94-5P
452315-97-8P 452316-00-6P 452316-03-9P
452316-06-2P 452316-09-5P 452316-12-0P
452316-15-3P 452316-18-6P 452316-21-1P
452316-24-4P 452316-27-7P 452316-30-2P
452316-33-5P 452316-36-8P 452316-39-1P
452316-42-6P 452316-45-9P 452316-48-2P
452316-51-7P 452316-53-9P 452316-55-1P
452316-58-4P 452316-64-2P 452316-66-4P
452316-69-7P 452316-72-2P 452316-75-5P
452316-81-3P 452316-84-6P 452316-87-9P
452316-89-1P 452316-91-5P 452316-93-7P
452316-95-9P 452316-97-1P 452316-99-3P
452317-02-1P 452317-04-3P 452317-06-5P
452317-08-7P 452317-10-1P 452317-12-3P
452317-14-5P 452317-16-7P 452317-18-9P
452317-20-3P 452317-22-5P 452317-24-7P
452317-26-9P 452317-28-1P 452317-30-5P
452317-32-7P 452317-34-9P 452317-36-1P
452317-38-3P 452317-40-7P 452317-42-9P
452317-44-1P 452317-46-3P 452317-48-5P
452317-50-9P 452317-52-1P 452317-54-3P
452317-56-5P 452317-58-7P 452317-60-1P
452317-64-5P 452317-67-8P 452317-69-0P
452317-71-4P 452317-73-6P 452317-76-9P
452317-79-2P 452317-82-7P 452317-84-9P
452317-86-1P 452317-89-4P 452317-92-9P
452317-94-1P 452317-96-3P 452317-99-6P
452318-02-4P 452318-04-6P 452318-07-9P
452318-09-1P 452318-11-5P 452318-13-7P
452318-15-9P 452318-18-2P 452318-20-6P
452318-22-8P 452318-24-0P 452318-27-3P
452318-30-8P 452318-32-0P 452318-34-2P
452318-36-4P 452318-38-6P 452318-41-1P
452318-43-3P 452318-45-5P 452318-47-7P
452318-49-9P 452318-52-4P 452318-54-6P
452318-57-9P 452318-60-4P 452318-63-7P
452318-65-9P 452318-67-1P 452318-69-3P
452318-71-7P 452318-73-9P 452318-75-1P
452318-77-3P 452318-79-5P 452318-81-9P
452318-83-1P 452318-85-3P 452318-87-5P
452318-89-7P 452318-91-1P 452318-93-3P
452318-95-5P 452318-97-7P 452318-99-9P
452319-01-6P 452319-03-8P 452319-05-0P
452319-07-2P 452319-09-4P 452319-11-8P
452319-13-0P 452319-15-2P 452319-17-4P
452319-20-9P 452319-22-1P 452319-24-3P
452319-25-4P 452319-27-6P 452319-29-8P
452319-31-2P 452319-33-4P 452319-35-6P

452319-37-8P 452319-39-0P 452319-41-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-40-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-43-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-46-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-50-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-61-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI)

(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-74-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-85-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methylphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dihydro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-98-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-05-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-butenyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452314-08-8 CAPLUS
CN 1-Piperazineethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-N-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-11-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-14-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452314-16-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-20-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-23-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-26-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-29-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(1,1,2,2-tetrafluoroethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-31-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-34-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-bromophenyl)methyl]-1-

piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-37-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-40-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-43-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452314-46-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-49-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-nitrophenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-52-2 CAPLUS
CN Benzenamine, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-

c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 452314-55-5 CAPLUS
CN Acetamide, N-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 452314-57-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-ethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-60-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME).



RN 452314-62-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-65-7 CAPLUS
CN 1-Propanamine, 3-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 452314-68-0 CAPLUS
CN Benzoic acid, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 452314-71-5 CAPLUS
CN Benzonitrile, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-74-8 CAPLUS
CN Benzonitrile, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-77-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-86-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-89-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-92-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-95-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-98-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-01-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thiazolylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-04-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-4-thiazolyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-07-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-10-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-13-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.



RN 452315-16-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-19-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-22-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-

phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-24-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-27-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-30-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-33-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-36-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3R,5S)-3,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-38-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,5S)-2,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-40-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[3-methyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-42-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452315-44-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452315-46-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-48-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-51-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-52-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(7-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-55-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-58-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-61-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-63-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-66-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-70-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-chloro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI)

(CA INDEX NAME)

Relative stereochemistry.



RN 452315-73-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(1-bromo-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-76-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-nitro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-79-6 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-82-1 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-85-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-87-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-90-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7,8-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-92-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-8-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-94-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-97-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-00-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride,

(3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-03-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-06-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-09-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-12-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-quinolinylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452316-15-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.



RN 452316-18-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-21-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-24-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-27-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-30-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-33-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-39-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-42-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-45-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-48-2 CAPLUS
CN 1H-Inden-1-one, 5-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethoxy]-2,3-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-51-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-[(2,3-dihydro-5-benzofuranyl)oxy]ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-53-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-55-1 CAPLUS
CN 3(2H)-Benzofuranone, 6-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methylethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-58-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[[(2R)-6-fluoro-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl]methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-64-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-66-4 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-69-7 CAPLUS
CN 1-Piperazinepropanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-72-2 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, oxime, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-75-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-81-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-84-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-87-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-89-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-91-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-93-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-phenoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-95-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-97-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-99-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-02-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452317-04-3 CAPLUS
CN Naphth[1,2-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-06-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-08-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-10-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-12-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-14-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-16-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-18-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-20-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[3-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-22-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[4-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-24-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(1,1,2,2-tetrafluoroethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-26-9 CAPLUS
CN Benzoic acid, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-28-1 CAPLUS
CN Benzoic acid, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-30-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-32-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-34-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-methylphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-36-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-phenoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-38-3 CAPLUS
CN Benzonitrile, 2-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-40-7 CAPLUS
CN Benzonitrile, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-42-9 CAPLUS
CN Benzonitrile, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-44-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-2-yl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-46-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,4-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-48-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,4-difluorophenyl)-2-

propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-50-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-52-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-54-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,5-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-56-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,5-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-58-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-dichlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-60-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-64-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-6-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-67-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-1H-inden-5-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-69-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-71-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9H-fluoren-2-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-73-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-dibenzofuranyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-76-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(1,3-benzodioxol-5-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-79-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-5-benzofuranyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-82-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4,5-dimethoxy-2-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-84-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-86-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI)

(CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-89-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-92-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromo-2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-94-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(5-bromo-2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-96-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-furanyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-99-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-02-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-04-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[5-(4-chlorophenyl)-2-furanyl]-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452318-11-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-quinolinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-13-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-quinolinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-15-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9-anthracenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 452318-18-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-1-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)-(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-22-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 452318-26-2
CMF C27 H33 N3 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 452318-30-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,5S)-2,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-32-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3R,5S)-3,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,6S)-2,6-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-36-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-

2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-38-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452318-41-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2,3-diphenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452318-43-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-[1,1'-biphenyl]-4-yl-3-phenyl-

2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-45-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-47-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(phenylmethylene)butyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-49-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-(phenylmethylene)heptyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-52-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-bromo-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-54-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-chloro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-57-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-60-4 CAPLUS
CN 1-Piperazinepropanenitrile, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-(phenylmethylene)-, (αZ)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-63-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-65-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-4-yl-2-methyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-67-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-79-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chloro-6-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-81-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-85-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-89-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-methyl-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-,

(3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-91-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2H-1-benzopyran-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-99-9 CAPLUS
CN Phenol, 3-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-05-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-dimethyl-3-thienyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-07-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-methyl-4-thiazolyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1-cyclopenten-1-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-15-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propynyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-17-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-20-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-22-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-4-(2-fluorophenyl)-2-methyl-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-24-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E,4E)-5-phenyl-2,4-pentadienyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-27-6 CAPLUS
CN Benzoic acid, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-33-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-37-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-39-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.



●2 HCl

RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-43-6P 452319-45-8P 452319-47-0P
452319-49-2P 452319-51-6P 452319-53-8P
452319-55-0P 452319-57-2P 452319-59-4P
452319-61-8P 452319-63-0P 452319-65-2P
452319-67-4P 452319-69-6P 452319-71-0P
452319-73-2P 452319-75-4P 452319-77-6P
452319-78-7P 452319-80-1P 452319-81-2P
452319-83-4P 452319-85-6P 452319-87-8P
452319-89-0P 452319-91-4P 452319-93-6P
452319-95-8P 452319-97-0P 452319-99-2P
452320-01-3P 452320-03-5P 452320-06-8P
452320-07-9P 452320-09-1P 452320-11-5P
452320-13-7P 452320-15-9P 452320-17-1P
452320-19-3P 452320-21-7P 452320-23-9P
452320-25-1P 452320-27-3P 452320-29-5P
452320-31-9P 452320-34-2P 452320-36-4P
452320-38-6P 452320-40-0P 452320-42-2P
452320-44-4P 452320-46-6P 452320-48-8P
452320-50-2P 452320-52-4P 452320-54-6P
452320-56-8P 452320-58-0P 452320-60-4P
452320-62-6P 452320-64-8P 452320-66-0P
452320-68-2P 452320-70-6P 452320-72-8P
452320-74-0P 452320-76-2P 452320-78-4P

452320-80-8P 452320-82-0P 452320-84-2P
452320-86-4P 452320-88-6P 452320-90-0P
452320-92-2P 452320-94-4P 452320-96-6P
452320-98-8P 452321-00-5P 452321-02-7P
452321-04-9P 452321-06-1P 452321-08-3P
452321-10-7P 452321-12-9P 452321-14-1P
452321-16-3P 452321-19-6P 452321-21-0P
452321-23-2P 452321-25-4P 452321-27-6P
452321-29-8P 452321-31-2P 452321-33-4P
452321-35-6P 452321-37-8P 452321-39-0P
452321-41-4P 452321-43-6P 452321-45-8P
452321-47-0P 452321-49-2P 452321-51-6P
452321-53-8P 452321-55-0P 452321-57-2P
452321-59-4P 452321-61-8P 452934-93-9P
452934-94-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452319-43-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-45-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-47-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-49-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452319-51-6 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-53-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, propanoate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS
CN Acetic acid, methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-

2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS
CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-

propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, rel-(3R,3aS)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-69-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-71-0 CAPLUS

CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-73-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, hydrogen sulfite (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-77-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-80-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-81-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-83-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7,8-difluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-85-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-87-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-phenyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-89-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-91-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-93-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452319-95-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-97-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-99-2 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-8-yl]oxy]-, acetate (ester), rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-03-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-06-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-11-5 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-13-7 CAPLUS
CN 3-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-15-9 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-17-1 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-

7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-19-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-21-7 CAPLUS
CN Carbonic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-23-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(2-propenyloxy)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-25-1 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452320-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, methanesulfonate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-29-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-31-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 452320-33-1
CMF C27 H33 N3 O3 S

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 452320-36-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-38-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-42-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-44-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(+)-

(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-46-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-48-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-50-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-56-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(phenylmethyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-58-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-68-2 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-72-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-74-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-76-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452320-78-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/513699

OMe

RN 452320-80-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-82-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-84-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(difluoromethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-86-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-7-[(tetrahydro-3-furanyl)oxy]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-88-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-90-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-92-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-94-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-96-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-00-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-02-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-04-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-06-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-08-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methylphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-16-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-19-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-23-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-pyridinyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-27-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-pyridinyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-33-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-35-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-37-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.



RN 452321-43-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-45-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyloxy)ethyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-47-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-49-2 CAPLUS
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452321-51-6 CAPLUS
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452321-53-8 CAPLUS
CN Furo[2',3':6,7]naphth[1,2-c]isoxazole, 3,3a,4,5,8,9-hexahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[2-[4-(2-naphthalenylmethyl)-1-piperazinyl]ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-methyl-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-59-4 CAPLUS
CN Formamide, N-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-61-8 CAPLUS
CN 1-Piperazinemethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-N-2-naphthalenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452934-93-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2,3,4a,8a-tetrahydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452934-94-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-3,4,4a,8a-tetrahydro-4-methyl-2H-1,4-benzoxazin-2-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:385709 CAPLUS
DOCUMENT NUMBER: 137:201371
TITLE: Novel ene-like cycloisomerization reaction of nitrile oxides with a tethered allyltrimethylsilyl group
AUTHOR(S): Ishikawa, Teruhiko; Urano, Jin; Ikeda, Shushiro; Kobayashi, Yasuhiro; Saito, Seiki
CORPORATE SOURCE: Department of Bioscience and Biotechnology, Faculty of Engineering, Okayama University, Okayama, 700-8530, Japan
SOURCE: Angewandte Chemie, International Edition (2002), 41(9), 1586-1588
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:201371
GI



I



II

AB Rather than the expected [3+2] cycloaddn., a novel ene-like cycloisomerization occurs on deprotonation of allyltrimethylsilyl-oxime compds. when the β-sp2 carbon atom of the allyltrimethylsilyl moiety is tethered to the oxime unit. The resulting nitrile oxide functional group serves as an enophile, and the final cyclized product still has two functional groups suitable for further manipulations. Thus, ene-like cycloisomerization of allyltrimethylsilyl-oxime I with NaOCl in CH2Cl2 gave 82% cyclized product II.
IT 452306-05-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 452306-05-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[(trimethylsilyl)methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:260283 CAPLUS
DOCUMENT NUMBER: 132:293757
TITLE: Preparation of novel 4,5-dihydroisoxazole derivatives and their use as pharmaceuticals for T cell-mediated diseases
INVENTOR(S): Freyne, Eddy Jean Edgard; Andres-Gil, Jose Ignacio; Deroose, Frederik Dirk; Petit, Davy Petrus Franciscus Maria; Matesanz-Ballesteros, Maria Encarnacion; Alvarez Escobar, Rosa Maria
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021959	A1	20000420	WO 1999-EP7803	19991007 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346396	A1	20000420	CA 1999-2346396	19991007 <--
EP 1119568	A1	20010801	EP 1999-953847	19991007 <--
EP 1119568	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527438	T	20020827	JP 2000-575865	19991007 <--
AU 763460	B2	20030724	AU 2000-10393	19991007
AT 259803	T	20040315	AT 1999-953847	19991007
ES 2216579	T3	20041016	ES 1999-953847	19991007
US 6583141	B1	20030624	US 2001-807149	20010406
HK 1038565	A1	20040618	HK 2002-100274	20020115
US 2004019059	A1	20040129	US 2003-403543	20030331
PRIORITY APPLN. INFO.:			EP 1998-203394 A	19981009
			WO 1999-EP7803 W	19991007
			US 2001-807149 A3	20010406

OTHER SOURCE(S): MARPAT 132:293757
GI



I



II

AB The invention concerns title compds. I and their N-oxides, pharmaceutically acceptable addition salts, quaternary ammonium salts, and stereochem. isomeric forms [wherein m, n, p = 0 or 1; R1 = (un)substituted pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl; B = amide, ketone, or oxadiazole; D = (un)substituted aryl or heterocyclyl; Q = bond, CO, (un)substituted NH, CONH, CH2, CH(:CH2), C(:NH), SO, SO, 3-oxobutenyl, pyrazole, isoxazole, or thiazole nucleus; L = (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-6 alkyloxy, or (un)substituted C1-6 alkyl]. Also disclosed is a process for their preparation, compns. comprising

them, and their medical use. The compds. show growth inhibitory activity against T cell blasts and keratinocytes in vitro. The compds. are claimed for use in the treatment of prevention of rheumatic, arthritic, and inflammatory diseases, psoriasis, T cell leukemia, transplant rejection, and graft-vs.-host disease. For instance, base-catalyzed cycloaddn. of N-hydroxy-3-pyridinecarboximidoyl chloride with Me 2-propenoate gave 98% Me 4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxylate, which was amidated with (4-aminophenyl)phenylmethanone to give 58% title compound II. At a concentration of 10-6 M, II gave 81% inhibition of T cell blast formation in human whole blood.

IT 264606-57-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-57-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline-3-carboxylic acid, 3,3a,4,5-tetrahydro- (9CI) (CA INDEX NAME)



IT 264606-16-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-16-8 CAPLUS

CN Piperidine, 4-(4-fluorobenzoyl)-1-[[(3R,3aR)-3,3a,4,5-tetrahydroisoxazolo[4,3-c]quinolin-3-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:191138 CAPLUS

DOCUMENT NUMBER: 128:257364
TITLE: Intramolecular cycloaddition of nitrones and nitrile oxides with sulfur-substituted dienes and its synthetic applications
AUTHOR(S): Chou, Shang-Shing P.; Yu, Yu-Ju
CORPORATE SOURCE: Dep. Chem., Fu Jen Catholic Univ., Taichung, 242, Peop. Rep. China
SOURCE: Journal of the Chinese Chemical Society (Taipei) (1998), 45(1), 163-173
CODEN: JCCTAC; ISSN: 0009-4536
PUBLISHER: Chinese Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:257364

AB A series of sulfur-substituted dienyl nitrones and oximes were conveniently prepared from the 3-sulfolene precursors. Regiospecific intramol. 1,3-dipolar cycloaddns. of nitrones and nitrile oxides with sulfur-substituted dienes have been efficiently carried out from the suitable 3-sulfolene precursors. The stereochem. of the cycloaddn. of nitrones depends on the structure of the substituent (sulfide or sulfone) on the diene as well as on the chain length connecting the diene and nitrone. The fused bicyclic products obtained from these reactions have been converted to some interesting heterocyclic compds. which have the useful structure of vinyl sulfide or sulfone.

IT 205110-63-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(intramol. cycloaddn. of nitrones and nitrile oxides with sulfur-substituted dienes)

RN 205110-63-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylthio)ethenyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:431584 CAPLUS
DOCUMENT NUMBER: 127:149098
TITLE: A convenient synthesis of 3- and 3,4-substituted 4,5-dihydroisoxazole-5-acetic acids
AUTHOR(S): Eichinger, Karl; Wokurek, Michael; Zauner, Bernd; Rostami, Mohammad Reza
CORPORATE SOURCE: Institute of Organic Chemistry, Vienna University of Technology, Vienna, A-1060, Austria
SOURCE: Synthetic Communications (1997), 27(16), 2733-2742
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Dekker

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:149098
GI



I

AB The 4,5-dihydroisoxazole-5-acetic acids I [R1 = Ph, Me, 4-ClC6H4, 4-MeOC6H4, 4-PhC6H4, R2 = H, SPh, OPh, 4-ClC6H4; R1R2 = (CH2)4, (CH2)10, 1,2,3,4-tetrahydronaphth-1,2-diyl] were prepared from the ketoximes R1C(CH2R2):NOH, 2,2-dimethyl-5-methoxymethylene-1,3-dioxan-4,6-dione and butyllithium in yields from 35 to 79 %.

IT 193267-45-7P 193267-49-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isoxazoleacetic acids)

RN 193267-45-7 CAPLUS
CN Naphth[1,2-c]isoxazole-3-acetic acid, 3,3a,4,5-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 193267-49-1 CAPLUS
CN 2,1-Benzisoxazole-3-acetic acid, 3,3a,4,5,6,7-hexahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:390560 CAPLUS
DOCUMENT NUMBER: 125:168364

TITLE: A highly convergent enantioselective total synthesis of marine natural product, furanoterpene
AUTHOR(S): Bando, Toshikazu; Shishido, Kozo
CORPORATE SOURCE: Inst. for Medicinal Resources, Univ. Tokushima, Sho, 770, Japan
SOURCE: Chemical Communications (Cambridge) (1996), (11), 1357-1358
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:168364
GI



I

AB The enantioselective total convergent synthesis of marine furanoterpene (I) is achieved and the absolute configuration of the only existing quaternary stereogenic center is found to be S.
IT 180333-99-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(a highly convergent enantioselective total synthesis of furanoterpene)
RN 180333-99-7 CAPLUS
CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7-[(methoxymethoxy)methyl]-7-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:29561 CAPLUS
DOCUMENT NUMBER: 124:232296
TITLE: Effect of the α-alkyl substituent of conjugated nitroolefins on the formation of cyclic nitronic esters vs. nitrocyclopropanes in their reaction with sulfur ylides
AUTHOR(S): Kumaran, G.; Kulkarni, Gurunath H.
CORPORATE SOURCE: Div. Org. Chem., Natl. Chem. Lab., Pune, 411008, India
SOURCE: Synthesis (1995), (12), 1545-8
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Thieme
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:232296
AB The formation of cyclic nitronic esters, isoxazoline N-oxides vs. nitrocyclopropanes in the reaction of conjugated nitroolefins with sulfur ylides depends on the presence of an α-alkyl substituent in the conjugated nitroolefins.
IT 174574-89-1P 174574-92-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(effect of alkyl substituent on cyclic nitronate and nitrocyclopropane formation in cycloaddn. of conjugated nitroolefins with sulfur ylides)
RN 174574-89-1 CAPLUS
CN 2,1-Benzisoxazole-3-carboxylic acid, 3,3a,4,5,6,7-hexahydro-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 174574-92-6 CAPLUS
CN Methanone, (3,3a,4,5,6,7-hexahydro-1-oxido-2,1-benzisoxazol-3-yl)phenyl- (9CI) (CA INDEX NAME)



L9 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:228191 CAPLUS
DOCUMENT NUMBER: 122:81272
TITLE: Nitrile oxide [3 + 2] cycloaddition: application to the synthesis of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones
AUTHOR(S): Baraldi, P. G.; Bigoni, A.; Cacciari, B.; Caldari, C.; Manfredini, S.; Spalluto, G.
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Univ. di Ferrara, Ferrara, I-44100, Italy
SOURCE: Synthesis (1994), (11), 1158-62
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Thieme
DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:81272

AB An efficient method for the preparation of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones starting from 3,5-disubstituted 4,5-dihydroisoxazoles is described. N-O bond cleavage of the isoxazoline ring promoted by molybdenum hexacarbonyl or by catalytic hydrogenation afforded the α-hydroxy γ-keto esters RCOCH2CH(OH)CO2Et (I, R = Me, Bu, 2-, 4-pyridyl, 4-HOC6H4) which were converted into 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones for 6-substituted 3(2H)-pyridazinones on treatment with hydrazine hydrate at room temperature or reflux in high yield starting from I. An intramol. version of this methodol. has been developed to prepare the known antiulcer tricyclic 5H-[1]-benzopyrano[4,3-c]pyridazin-3(2H)-one.

IT 160427-31-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(nitrile oxide [3 + 2] cycloaddn. to pyridazinones)

RN 160427-31-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:94454 CAPLUS
DOCUMENT NUMBER: 123:111970
TITLE: Pyridazin-3(2H)-ones via Δ2-isoxazoline intermediates: synthetic studies
AUTHOR(S): Baraldi, Pier Giovanni; Spalluto, Giampiero; Manfredini, Stefano; Simoni, Daniele
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Ferrara, Italy
SOURCE: Acta Chimica Slovenica (1994), 41(2), 149-72
CODEN: ACSLE7; ISSN: 1318-0207
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB An efficient method for the preparation of 6-substituted-4,5-dihydro-3(2H)pyridazinones I (R = alkyl, benzyl, etc.) was described. The synthetic strategy is based on Δ2-isoxazolines chemical which were unmasked by N-O bond cleavage and cyclized to the target compound Utilizing the same approach was possible to obtain both 6-substituted-3(2H)-pyridazinones and 6-substituted-4-hydroxy-4,5-dihydro-3(2H)-pyridazinones. This protocol was also extended to a C-nucleoside starting from β-ribofuranosylnitromethane. Moreover, an intramol. version of this methodol. has been developed to prepare a known antiulcer tricyclic 3(2H)-pyridazinone. The unusual transformation of compds. I into the corresponding 3-(1-naphthyl)propionic acid Et ester derivs. was also reported.

IT 160427-31-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzpyranopyridazinone)

RN 160427-31-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:560649 CAPLUS
DOCUMENT NUMBER: 119:160649
TITLE: Preparation of secosteroids having vitamin D activities.
INVENTOR(S): Sotojima, Fukuo
PATENT ASSIGNEE(S): Juki Gosei Yakuhin Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05058991	A	19930309	JP 1991-254255	19910906 <--

PRIORITY APPLN. INFO.: JP 1991-254255 19910906
OTHER SOURCE(S): CASREACT 119:160649; MARPAT 119:160649
GI



AB The title compds. [R1, R2 = H, protecting group] are prepared in many steps from a heptenetriol derivative, e.g., HO-CH2-CH:CH-CH2-CHQ-CH2-CH2-O-Q1 [Q = tert-butyldiphenylsilyl, Q1 = p-methoxyphenyl]. E.g., the (nitrooctenylidene)cyclohexane derivative II (multistep preparation given) was cyclized in benzene contg Et3N and Ph isocyanate to give III diastereomers, one of which in H2O containing B(OMe)3 was treated with Raney Ni in EtOH to give I [R1 = R2 = Q].

IT 149741-09-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring cleavage of)

RN 149741-09-3 CAPLUS

CN 2,1-Benzisoxazole, 3-(cyclohexylidenemethyl)-7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,3a,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



L9 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:234262 CAPLUS

DOCUMENT NUMBER: 118:234262

TITLE: A general synthetic route to fused furans. Total synthesis of (+)-pallescensin A

AUTHOR(S): Shishido, Kozo; Umimoto, Koji; Ouchi, Mikiko; Irie, Osamu; Omodani, Tomoki; Takata, Takeshi; Shibuya, Masayuki

CORPORATE SOURCE: Inst. Med. Resour., Univ. Tokushima, Tokushima, 770, Japan

SOURCE: Journal of Chemical Research, Synopses (1993), (2), 58-9
CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A general and facile synthetic route to fused furans has been developed. The key step of the transformation involves the intramol. [3+2] dipolar cycloaddn. reaction of nitrile oxides which were generated in situ from the corresponding oxime acetates. Reductive hydrolysis of the resulting dihydroisoxazoles followed by alkaline hydrolysis provided β,γ-dihydroxy ketones which were immediately treated with a catalytic amount of p-toluenesulfonic acid to afford the fused furans I (R = Me, R1 = H; R = H, R1 = Me). Alternatively, the alcs., derived by hydrolysis of the dihydroisoxazoles, were submitted to a sequential reductive hydrolysis and acid treatment to provide I. Addnl. dihydroisoxazole alcs., prepared from com. available phthalide, were similarly treated to give the tricyclic fused furans II (R2 = H, Me, R3 = Me; R2 = Me, R3 = H) in reasonable yields. The methodol. developed here has been successfully applied to a total synthesis of (+)-pallescensin A (III) starting with (+)-Wieland-Miescher ketone.

IT 147378-13-0P 147511-14-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacetylation of)

RN 147378-13-0 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-α-methyl-, acetate (ester), [3α(S*),3aα]- (9CI) (CA INDEX NAME)



RN 147511-14-6 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-α-methyl-, acetate (ester), [3α(R*),3aα]- (9CI) (CA INDEX NAME)



IT 129302-93-8P 147378-09-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reductive hydrolysis of)

RN 129302-93-8 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5,5a,6,7,8,9,9a-decahydro-6,6,9a-trimethyl-, acetate (ester), [3R-(3α,3aα,5aβ,9aα)]- (9CI) (CA INDEX NAME)



RN 147378-09-4 CAPLUS
CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7,7-dimethyl-, acetate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 147378-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, deacetylation, and cyclization of)

RN 147378-18-5 CAPLUS
CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7,7-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 147378-22-1P 147511-12-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, hydrolysis, and cyclization of)

RN 147378-22-1 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-α-methyl-, [3α(S*),3aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 147511-12-4 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-α-methyl-, [3α(R*),3aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	1992:570854 CAPLUS
DOCUMENT NUMBER:	117:170854
TITLE:	Preparation of (dihydroxyethyl)cyclohexanone derivatives as intermediates for ring A fragments of compounds having vitamin D-like activity
INVENTOR(S):	Sotojima, Fukuo
PATENT ASSIGNEE(S):	Yuki Gosei Yakuhin Kogyo K. K., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 17 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04082856	A	19920316	JP 1990-194847	19900725 <--
PRIORITY APPLN. INFO.:			JP 1990-194847	19900725

OTHER SOURCE(S): CASREACT 117:170854; MARPAT 117:170854
GI



I

II



IV



V

AB The title compds. I (R1-R4 = H, OH-protecting group) are prepared from CH2:CHCH2CH2OR5 (R5 = H, OH-protecting group) via intermediates such as epoxides (II), alkynes R3OCH2C.tplbond.CCH2CH(OR1)CH2CH2OR5 (III; R1, R3, R5 = same as above), olefins [IV; R = CH2OR5, CHO, CH(OR2)CH2NO2; R1, R2, R3, R5 = same as above], and isoxazole derivs. (V; R1-R3 = same as above). Thus, ring-opening addition reaction of II (R5 = CH2C6H4OMe-p)(preparation given) with HC.tplbond.CCH2OTHP (THP = terahydropyranyl) in the presence of BF3.Et2O after metalation with BuLi, conversion of the resulting III (R1 = H, R3 = THP, R5 = CH2C6H4OMe-p) into IV (R = CHO, R1 = SiPh2Bu-tert, R3 = THP) via silylation, debenzylation, partial hydrogenation over Lindlar catalyst, and oxidation with pyridinium chlorochromate, and addition reaction of the aldehyde with MeNO2 in the presence of KF and 18-crown-6 gave IV [R = CH(OH)CH2NO2, R1 = SiPh2Bu-tert, R3 = THP]. Silylation of the last with CF3SO3SiMe2Bu-tert in the presence of 2,6-lutidine, cyclization of the resulting IV [R = CH(OSiMe2Bu-tert)CH2NO2, R1 = SiPh2Bu-tert, R3 = THP] by treatment with Et3N and PhCNO, and hydrogenation of the resulting V (R1, R3 = same as above; R2 = SiMe2Bu-tert) over Raney nickel in the presence of H2O gave I (R = SiPh2Bu-tert, R2 = SiMe2Bu-tert, R3 = THP, R4 = H).

IT 142860-74-0P 142860-82-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in preparation of cyclohexanone derivative as intermediate for ring A fragment of vitamin D analog)

RN 142860-74-0 CAPLUS
CN 2,1-Benzisoxazole, 7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,3a,4,5,6,7-hexahydro-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 142860-82-0 CAPLUS
CN 2,1-Benzisoxazole, 5,7-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,3a,4,5,6,7-hexahydro-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:532531 CAPLUS
DOCUMENT NUMBER: 113:132531
TITLE: An alternative total synthesis of (+)-pallescensin A based on the intramolecular [3+2] cycloaddition reaction
AUTHOR(S): Shishido, Kozo; Umimoto, Koji; Shibuya, Masayuki
CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokushima, Tokushima, 770, Japan
SOURCE: Heterocycles (1990), 31(4), 597-8
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:132531
GI



I



II

AB An alternative total synthesis of optically active pallescensin A (I) features a furan construction via the intramol. [3+2] cycloaddn. of nitrile oxide II.

IT 129302-93-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and isoxazoline reductive hydrolysis of)

RN 129302-93-8 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5,5a,6,7,8,9,9a-decahydro-6,6,9a-trimethyl-, acetate (ester), [3R-(3α,3aα,5aβ,9aα)]- (9CI) (CA INDEX NAME)



L9 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:458998 CAPLUS

DOCUMENT NUMBER: 113:58998

TITLE: Reaction of Cα,O-dilithiooximes with functionalized carbonyl compounds. Part 2. Reaction with α-chloroketones and α,β-unsaturated aldehydes and ketones

AUTHOR(S): Jarrar, Adil A.; Hussein, Ahmad Q.; Madi, Ahmad S.

CORPORATE SOURCE: Fac. Sci., Univ. Jordan, Amman, Jordan

SOURCE: Journal of Heterocyclic Chemistry (1990), 27(2), 275-8
CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:58998

GI



AB Reaction of LiON:CRCHR1Li (I; R = Ph, 4-MeC6H4; R1 = H) with 4-R2C6H4COCH2Cl (R2 = H, Me) afforded (hydroxymethyl)isoxazoline II in 62-77% yield. Similar reaction of I [R = Ph, 4-MeC6H4, 4-BrC6H4, R1 = H; RR1 = (CH2)4] with R3COCH:CR3R4 (R3 = H, Me; R4 = H, Me, Ph) gave HON:CRCHR1CR3(OH)CH:CR3R4 (III) in 63-80% yield. Treatment of III with

P2O5 gave vinylisoxazolines IV.

IT 128094-36-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 128094-36-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(2-phenylethenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:477887 CAPLUS

DOCUMENT NUMBER: 111:77887

TITLE: Stepwise intramolecular cycloaddition of nitrile oxide equivalents derived from the Lewis acid-promoted reaction of 1-nitroalkadienes and allylic stannanes

AUTHOR(S): Uno, Hidemitsu; Goto, Kenichi; Watanabe, Noriko; Suzuki, Hitomi

CORPORATE SOURCE: Fac. Sci., Ehime Univ., Matsuyama, 790, Japan

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1989), (2), 289-95
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:77887

AB The Lewis acid-promoted reaction of 1-nitroalka-1,5-(or 1,6-)dienes with allylic stannanes has been studied. In the presence of TiCl4, 1-nitrohexa-1,5-diene reacted smoothly with allyltrimethylstannane to give a diastereoisomeric mixture of 6-allyl-3a,4,5,6-tetrahydro-3H-cyclopent[c]isoxazoles, while the reaction using AlCl3 as catalyst led to an allylated cyclohexanone oxime derivative in good yield. Similar reaction of 1-nitrohepta-1,6-diene, however, gave a bicyclic dihydroisoxazole irresp. of the Lewis acids employed. In the latter case, nitrile oxide equivs. derived from 1-nitroalka-1,6-dienes underwent a stepwise cycloaddn. as shown by the lack of stereospecificity in the reactions of (1E,6Z)-1-nitro-7-phenylhepta-1,6-diene and (1E,6Z)-1-nitrooocta-1,6-diene.

IT 121948-65-0P 122045-15-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectra of)

RN 121948-65-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-7-(2-propenyl)-, (3α,3aα,7β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 122045-15-2 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-7-(2-propenyl)-, (3α,3aβ,7α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:21762 CAPLUS
DOCUMENT NUMBER: 108:21762
TITLE: Stereoselective intramolecular nitrile oxide cycloaddition to chiral allyl ethers
AUTHOR(S): Annunziata, Rita; Cinquini, Mauro; Cozzi, Franco; Raimondi, Laura
CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milano, Milan, I-20133, Italy
SOURCE: Journal of the Chemical Society, Chemical Communications (1987), (8), 529-30
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:21762
GI



AB Intramol. nitrile oxide cycloaddn. reactions on (Z)- and (E)-chiral allyl ethers occur with poor to good stereoselectivity (diastereoisomeric ratios up to 86:14), which depends on the double bond configuration as well as on

steric and stereoelectronic effects. Thus, PhCH2OCHMeCH:CH(CH2)4CH:NOH was treated with NaOCl to give isoxazole derivs. I and II.
IT 109960-80-7P 109960-81-8P 110013-28-0P
110013-29-1P 110013-30-4P 110013-31-5P
110013-32-6P 110013-33-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 109960-80-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109960-81-8 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-28-0 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-29-1 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-30-4 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-31-5 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-32-6 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-33-7 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:575238 CAPLUS
DOCUMENT NUMBER: 107:175238
TITLE: Stereoselectivity of intramolecular nitrile oxide cycloadditions to Z and E chiral alkenes
AUTHOR(S): Annunziata, Rita; Cinquini, Mauro; Cozzi, Franco; Gennari, Cesare; Raimondi, Laura
CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milano, Milan, I-20133, Italy
SOURCE: Journal of Organic Chemistry (1987), 52(21), 4674-81
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:175238

AB Treatment of (E)- and (Z)-RCHR1CH:CHCH2CH2(CH2)nCH:NOH [R = PhCH2O, PhCH2OCH2, Me2CH; R1 = Me, PhCH2O; RR1 = O(CH2)5OCH2] with NaOCl gave nitrile oxides, which were trapped by intramol. cycloaddn. to give isoxazoline diastereoisomer mixts. The anal. of the products was combined with MM2 calcns. on the transition structures. With the (E)-alkenes,

electronic factors govern the stereoselectivity; with the (Z)-alkenes steric factors are more important.

IT 109960-99-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 109960-99-8 CAPLUS

CN 1,2-Ethanediol, 1-(3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)-, 2-(4-methylbenzenesulfonate), [3S-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)



IT 109960-98-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)

RN 109960-98-7 CAPLUS

CN 1,2-Ethanediol, 1-(3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)-, [3S-[3α(S*),4β]]- (9CI) (CA INDEX NAME)



IT 109960-80-7P 109960-81-8P 109960-83-0P
110013-28-0P 110013-29-1P 110013-30-4P
110013-31-5P 110013-32-6P 110013-33-7P
110013-37-1P 110013-38-2P 110013-39-3P
110013-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 109960-80-7 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109960-81-8 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109960-83-0 CAPLUS

CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(S*),3aβ]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110013-28-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-29-1 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-30-4 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-31-5 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-32-6 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3α(S*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-33-7 CAPLUS
CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3α(R*),3aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110013-37-1 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(R*),3aβ]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110013-38-2 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(S*),4α]- (9CI) (CA INDEX NAME)



RN 110013-39-3 CAPLUS
CN 2,1-Benzisoxazole, 3-(1,2-dimethylpropyl)-3,3a,4,5,6,7-hexahydro-, [3α(R*),3aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110013-46-2 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(S*),4β]]- (9CI) (CA INDEX NAME)



L9 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1985:560616 CAPLUS
DOCUMENT NUMBER: 103:160616
TITLE: Oxidative fragmentation of β-stannyl oximes: stereospecific formation of unsaturated nitrile oxides
AUTHOR(S): Nishiyama, Hisao; Arai, Hiroyuki; Ohki, Takashi; Itoh, Kenji
CORPORATE SOURCE: Sch. Mater. Sci., Toyohashi Univ. Technol., Tempaku, 440, Japan
SOURCE: Journal of the American Chemical Society (1985), 107(18), 5310-12
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:160616
GI



AB A new stereospecific oxidative-fragmentation was found by treatment of cyclic (E)-β-tributylstannyl oximes (I, R = H, R1 = Me; R = Me, R1 = H) with lead tetraacetate to give the unsatd. nitrile oxides II which gave in one-pot the Δ2-isoxazolines III, resp., via intramol. 1,3-dipolar cycloaddn. Dramatic conversion of their cyclic skeleton was completely controlled by the stannyl function. It is noteworthy that the linear (Z)-β-stannyl oximes IV (R1 = Ph, Me3C) gave directly the cyclization products V. Stereoselectivity of the fragmentation of several linear oximes was also demonstrated. Stereocontrolled homolytic process via iminoxyl radicals, generated by oxidation of the oximes, could be postulated.
IT 97782-43-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 97782-43-9 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1983:505163 CAPLUS
DOCUMENT NUMBER: 99:105163
TITLE: Reduction of Δ2-isoxazolines. 3. Raney nickel catalyzed formation of β-hydroxy ketones
AUTHOR(S): Curran, Dennis P.
CORPORATE SOURCE: Dep. Chem., Univ. Pittsburgh, Pittsburgh, PA, 15260, USA
SOURCE: Journal of the American Chemical Society (1983), 105(18), 5826-33
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 99:105163
GI



AB Olefins underwent [2 + 3] dipolar cycloaddn. with nitrile oxides to give 2-isoxazolines, which were transformed to β-hydroxy ketones with Raney Ni catalyst, boric acid, 5:1 MeOH-H2O, and H. This cycloaddn.-reduction

sequence allowed diastereospecific formation of threo and erythro products. Thus cycloaddn. of RCNO (R = Me, Ph) with trans-2-butene gave isoxazolines trans-I, which were reduced to threo-RCOCHMeCHMeOH (threo-II), while cis-2-butene gave cis-I, and erythro-II upon reduction

IT 82150-04-7P 82150-10-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of, β-hydroxyketones by)

RN 82150-04-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 82150-10-5 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1982:509909 CAPLUS
DOCUMENT NUMBER: 97:109909
TITLE: Reduction of Δ2-isoxazolines: a conceptually different approach to the formation of aldol adducts
AUTHOR(S): Curran, Dennis P.
CORPORATE SOURCE: Dep. Chem., Univ. Pittsburgh, Pittsburgh, PA, 15260, USA
SOURCE: Journal of the American Chemical Society (1982), 104(14), 4024-6
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The isoxazolines I [R1 = H, Me, Pr; R2 = H, Me; R3 = Me, Pr, Bu, Ph; R1R2 = (CH2)4, (CH2)3, R3 = H], prepared by nitrile oxide-olefin cycloaddn., underwent reduction by H2 in presence of Raney Ni to give the aldol adducts II. The cycloalkaisoxazoline III (n = 1, 2; R3 = H, Me, Ph; R4 = H, Me, Ph, CH2OAc) were similarly reduced to give the aldol adducts IV.

IT 82150-04-7 82150-10-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(catalytic reduction of)

RN 82150-04-7 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 82150-10-5 CAPLUS
CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1972:488371 CAPLUS
DOCUMENT NUMBER: 77:88371
TITLE: Reaction of keto-stabilized sulfonium and arsonium ylides with α-chlorooximes. New synthesis of Δ2-isoxazolines
AUTHOR(S): Bravo, P.; Gaudiano, G.; Ponti, P. P.; Ticozzi, C.

CORPORATE SOURCE: Ist. Chim., Politec. Milano, Milan, Italy
SOURCE: Tetrahedron (1972), 28(14), 3845-54
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 77:88371

GI For diagram(s), see printed CA Issue.

AB The reaction of α-chloro oximes or the isomeric nitroso chlorides with keto-stabilized dimethylsulfonium or triphenylarsonium ylides gave trans-5-acyl-2-isoxazolines (I, e.g., R, R1 = Me, Ph, R2 = Bz). The NOCl adducts of Et propenyl ether and Et styryl ether on reaction with dimethylsulfonium phenacylide gave 3-substituted 5-benzoylisoxazoles. Dimethylsulfonium carbethoxymethylide (II) and 2-chloro-2-phenylacetone oxime gave Et β-acetylcinnamate oxime. II and 2-chlorocyclooctanone oxime gave the thioether (III).

IT 37543-31-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37543-31-0 CAPLUS

CN Methanone, (3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> FIL STNGUIDE
=>

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.51	573.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-17.16	-29.64

FILE 'STNGUIDE' ENTERED AT 15:34:43 ON 27 APR 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 20, 2007 (20070420/UP).

[redacted] 10/524,123 search after election

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	PORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

<12/04/2007> Erich Leese

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:48:58 ON 25 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:49:08 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2007 HIGHEST RN 947820-54-4
DICTIONARY FILE UPDATES: 24 SEP 2007 HIGHEST RN 947820-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10524123election.str

L1 . STRUCTURE UPLOADED

=> s l1 full
FULL SEARCH INITIATED 15:50:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10524123compound20.str

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS

<12/04/2007> Erich Leese

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l3 full
FULL SEARCH INITIATED 15:54:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\10524123pyridinyl.str

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 C,O,S,N

G2 C,N

G3 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l5 full
FULL SEARCH INITIATED 15:56:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1403 TO ITERATE

100.0% PROCESSED 1403 ITERATIONS 689 ANSWERS
SEARCH TIME: 00.00.01

L6 689 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	520.80	521.01

<12/04/2007> Erich Leese

FILE 'CAPLUS' ENTERED AT 15:56:42 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 24 Sep 2007 (20070924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6 full
L7 14 L6

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2007:474148 CAPLUS
DOCUMENT NUMBER:	146:492615
TITLE:	Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism
AUTHOR(S):	Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Drinkenburg, Wilhelmus; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Langlois, Xavier; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Pullan, Shirley; Steckler, Thomas
CORPORATE SOURCE:	Research & Early Development-EU, CNS-Psychiatry, Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
SOURCE:	Bioorganic & Medicinal Chemistry (2007), 15(11), 3649-3660 CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER:	Elsevier Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 146:492615
GI	

<12/04/2007> Erich Leese



AB In previous articles we have described the discovery of a new series of tricyclic isoxazolines combining central serotonin (5-HT) reuptake inhibition with α2-adrenoceptor antagonistic activity. We report now on the synthesis, the in vitro binding potency and the primary in vivo activity of six enantiomers within this series, one of which was selected for further pharmacol. evaluation and assigned as R226161 (I). Some addnl. in vivo studies in rats are described with this compound, which proved to be centrally and orally active as a combined 5-HT reuptake inhibitor and α2-adrenoceptor antagonist.

IT 452313-46-1P 452313-65-4P 452313-68-7P
452313-71-2P 452314-01-1P 452318-73-9P
452318-75-1P 722545-47-3P 936362-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism)

RN 452313-46-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452313-68-7 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-

2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 936362-34-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 452313-36-9 452318-26-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism)

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 936362-26-4P 936362-28-6P 936362-31-1P
936362-33-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism)
RN 936362-26-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 936362-28-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 936362-31-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 936362-33-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:511158 CAPLUS
DOCUMENT NUMBER: 145:27976
TITLE: Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity
INVENTOR(S): Andres-Gil, Jose Ignacio; Bartolome-Nebreda, Jose Manuel; Alcazar-Vaca, Manuel Jesus; Garcia-Martin, Maria de las Mercedes; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056600	A1	20060601	WO 2005-EP56229	20051125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005308778	A1	20060601	AU 2005-308778	20051125
CA 2585857	A1	20060601	CA 2005-2585857	20051125
EP 1819713	A1	20070822	EP 2005-816247	20051125
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRIORITY APPLN. INFO.:			EP 2004-106123	A 20041126
			WO 2005-EP56229	W 20051125

OTHER SOURCE(S): MARPAT 145:27976
GI



I



II

AB Title compds. I [X = CH2, S, O, (un)substituted-N; V = S, O, NH, or NR4 wherein R4 = alkyl or covalent bond between the N and the (CH2)n moiety; R1 and R2 independently = H, halo, OH, aryl, etc.; R3 = H, CN, halo, alkyl, etc.; q = 0-2; m = 0-3; n = 0-4; A = bivalent radical chosen from (un)substituted piperidinyl which is optionally partially unsatd. or (un)substituted alkyl amine], and their pharmaceutically acceptable salts are prepared and disclosed as having a binding affinity towards dopamine receptors, in particular towards dopamine D2 and/or D3 receptors, with selective serotonin reuptake inhibition (SSRI) properties and showing an affinity for the 5-HT1A receptor. Thus, e.g., II was prepared by substitution of 3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazole-3-methanol methanesulfonate ester with 5-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole. In binding assays for 5-HT1A receptor, I possessed pIC50 values ranging from 6.0-8.9. Further disclosed are pharmaceutical compns. comprising I, the use thereof for the prevention and/or treatment of a range of psychiatric and neurol. disorders, in particular certain psychotic disorders, most in particular schizophrenia and processes for their production
IT 888727-48-8P 888727-56-8P 888727-58-0P
888727-84-2P 888727-97-7P 888727-98-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)
RN 888727-48-8 CAPLUS
CN 1H-Indol-5-ol, 3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-56-8 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, acetate (ester), rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 888727-58-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-84-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-bromo-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(5-methoxy-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 888727-46-6P 888727-47-7P 888727-49-9P
888727-50-2P 888727-51-3P 888727-52-4P
888727-53-5P 888727-54-6P 888727-55-7P
888727-57-9P 888727-59-1P 888727-60-4P
888727-61-5P 888727-62-6P 888727-63-7P
888727-65-9P 888727-66-0P 888727-67-1P

888727-68-2P 888727-69-3P 888727-71-7P
888727-72-8P 888727-73-9P 888727-74-0P
888727-75-1P 888727-76-2P 888727-77-3P
888727-78-4P 888727-79-5P 888727-80-8P
888727-81-9P 888727-82-0P 888727-83-1P
888727-85-3P 888727-86-4P 888727-87-5P
888727-88-6P 888727-89-7P 888727-91-1P
888727-92-2P 888727-93-3P 888727-94-4P
888727-95-5P 888727-96-6P 888727-99-9P
888728-00-5P 888728-01-6P 888728-02-7P
888728-03-8P 888728-04-9P 888728-05-0P
888728-06-1P 888728-08-3P 888728-09-4P
888728-10-7P 888728-32-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 888727-46-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-47-7 CAPLUS
CN 1H-Indol-5-ol, 3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-49-9 CAPLUS

CN 1H-Indol-6-ol, 1-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-50-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-methyl-1H-indol-3-yl)-1-piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-51-3 CAPLUS
CN 1H-Indol-5-amine, 3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-52-4 CAPLUS
CN Acetamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-1H-indol-5-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-53-5 CAPLUS
CN Urea, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-54-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(1-methyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-55-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-methoxy-1H-indol-3-yl)-1-piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-57-9 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-59-1 CAPLUS
CN Acetamide, N-[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-60-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[5-[(2-methoxyethoxy)methoxy]-1H-indol-3-yl]-1-piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 888727-61-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-phenyl-1H-indol-3-yl)-1-piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-62-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-63-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-65-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-3-yl)-1-piperidinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 888727-64-8
CMF C26 H29 N3 O4

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 888727-66-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(4-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-67-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-68-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-72-8 CAPLUS
CN Acetic acid, ethoxy-, 2-[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

OEt

RN 888727-73-9 CAPLUS
CN Carbamic acid, ethyl-, 2-[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

NHEt

RN 888727-74-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-76-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-78-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-79-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(7-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-80-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-81-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-bromo-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-82-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-(1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl)-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-85-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-86-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-88-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-89-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-91-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA

INDEX NAME)

Relative stereochemistry.



RN 888727-92-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-94-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-

, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

RN 888727-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-96-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-99-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(5-methyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-00-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(5-nitro-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,6-dihydro-4-(5-phenyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-02-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-03-8 CAPLUS
CN Urea, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-04-9 CAPLUS
CN Glycine, N-[[[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 888728-05-0 CAPLUS
CN Acetamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-2-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-06-1 CAPLUS
CN Acetic acid, [[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]amino]oxo-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 888728-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-3-benzofuranyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-32-3 CAPLUS
CN 1H-Indol-5-amine, 3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 888728-31-2
CMF C26 H28 N4 O4

Relative stereochemistry.





RN 888728-08-3 CAPLUS
CN Methanesulfonamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 888728-07-2
CMF C27 H30 N4 O6 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 888728-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-fluoro-1H-indol-3-yl)methyl]-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 888728-28-7P 888728-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)
RN 888728-28-7 CAPLUS
CN Carbamic acid, [3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 888728-29-8 CAPLUS
CN Carbamic acid, [(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:505909 CAPLUS
DOCUMENT NUMBER: 145:95782
TITLE: Synthesis of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivatives displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities
AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; De Lucas, Ana I.; Iturrino, Laura; Biesmans, Ilse; Megens, Anton A.
CORPORATE SOURCE: Medicinal Chemistry Department, Division of Janssen-Cilag, Johnson & Johnson Pharmaceutical Research and Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4361-4372
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:95782

AB Following a program searching for dual 5-HT reuptake inhibitors and α2-adrenoceptor antagonists started at Johnson & Johnson Pharmaceutical Research & Development, we now report on the synthesis of a series of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivs., some of which proved to be the most potent α2-adrenoceptor blockers within this chemical class of tricyclic isoxazolines, while keeping potent 5-HT reuptake inhibiting activity.

IT 612074-52-9P 612074-56-3P 612074-57-4P
612074-68-7P 612074-81-4P 612074-88-1P
612074-89-2P 612074-90-5P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-98-3P 612074-99-4P 612075-02-2P
612075-03-3P 612075-07-7P 612075-09-9P
612075-10-2P 612075-11-3P 612075-12-4P
612075-13-5P 612075-15-7P 612075-88-4P
770707-27-2P 895169-63-8P 895169-64-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzopyranoisoxazole derivs. displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 612074-52-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-56-3 CAPLUS
CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-57-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-dimethoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-68-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-94-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-95-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-98-3 CAPLUS
CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-

propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-99-4 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-02-2 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-03-3 CAPLUS
CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-09-9 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-10-2 CAPLUS
CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS
CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-15-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-88-4 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 770707-27-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 895169-63-8 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 895169-64-9 CAPLUS
CN Ethanol, 2-[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 452318-26-2 452319-41-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzopyranoisoxazole derivs. displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)
RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-29-8P 612074-55-2P 895169-62-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzopyranoisoxazole derivs. displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)
RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-55-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 895169-62-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:920735 CAPLUS
DOCUMENT NUMBER: 142:219240
TITLE: Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α2-Adrenoceptor Blocking Activity
AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Font, Luis M.; Hens, Koen A.; Iturrino, Laura; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Vermote, Patrick C. M.; Steckler, Thomas
CORPORATE SOURCE: Johnson Johnson Pharmaceutical Research Development Division of Janssen-Cilag Medicinal Chemistry dept., Jarama s/n, Toledo, 45007, Spain
SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 2054-2071
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:219240

AB The synthesis and pharmacol. of a new series of 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that combine central serotonin (5-HT) reuptake inhibition with α2-adrenoceptor blocking activity is described as potential antidepressants. Four compds. were selected for further evaluation, and the combination of both activities was found to be stereoselective, residing mainly in one enantiomer. Reversal of the loss of righting induced by the α2-agonist medetomidine in rats confirmed the α2-adrenoceptor blocking activity in vivo and also demonstrated CNS penetration. Antagonism of p-chloroamphetamine (pCA)-induced excitation as well as blockade of the neuronal 5-HT depletion induced by p-CA administration in rats confirmed their ability to block the central 5-HTT, even after oral administration. Replacement of the oxygen atom at the 5-position of the tricyclic scaffold by a nitrogen or a carbon atom, as well as O-substitution at position 7, led also to active compds., both in vitro and in vivo.

IT 452313-54-1P 452318-20-6P 452318-95-5P
608146-13-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)



RN 608146-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452319-41-4
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)
RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452313-65-4P 452319-33-4P 452320-36-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

RN 452313-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.

preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)
RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-33-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-36-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452313-36-9P 452313-59-6P 452313-77-8P
452318-26-2P 452318-93-3P 452319-43-6P
452319-55-0P 452319-57-2P 452319-59-4P
452319-61-8P 452319-63-0P 452319-65-2P
452319-67-4P 452319-69-6P 452319-71-0P
452320-40-0P 452320-52-4P 452320-54-6P
452320-60-4P 452320-62-6P 452320-64-8P
452320-66-0P 452320-70-6P 452321-33-4P
452321-35-6P 452321-37-8P 452321-39-0P
452321-41-4P 789484-08-8P 815632-62-3P
815632-63-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-59-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-43-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, propanoate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS
CN Acetic acid, methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS
CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-69-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-71-0 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-33-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-35-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-37-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 815632-62-3 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 815632-63-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452313-56-3P 452318-24-0P 452318-97-7P
608146-12-9P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)
RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 789484-08-8 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 452321-75-4P 452321-82-3P 452322-19-9P
452322-21-3P 452322-23-5P 815632-58-7P
815632-59-8P 815632-60-1P 815632-61-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α2-adrenoceptor blocking activity)
RN 452321-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-82-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-19-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-21-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-23-5 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 815632-58-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydronaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 815632-59-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7-methoxynaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 815632-60-1 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 815632-61-2 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:760314 CAPLUS
DOCUMENT NUMBER: 141:384410
TITLE: A screening strategy for the development of enantiomeric separation methods in capillary electrophoresis
AUTHOR(S): Jimidar, M. Ilias; van Ael, Willy; van Nyen, Patrick; Peeters, Margot; Redlich, Dirk; de Smet, Maurits
CORPORATE SOURCE: Pharmaceutical Research & Development (J&J-PRD) A division of Janssen Pharmaceutica n.v., Global Analytical Development, Johnson and Johnson, Beerse, Belg.
SOURCE: Electrophoresis (2004), 25(16), 2772-2785
CODEN: ELCTDN; ISSN: 0173-0835
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Method development of enantiomeric sepns. in capillary electrophoresis (CE) is a time-consuming task, since finding the appropriate chiral selector is usually a "trial and error" process. It is impossible to predict the selectivity of a selector towards a certain enantiomer. Therefore, the affinity of all selectors has to be examined one at a time. In order to speed up this process, a strategy is proposed based on simple exptl. design methodol. The approach includes first a screening in function of the pH to determine the optimal migration conditions followed by a selection of the right chiral selector by means of Taguchi designs. In the approach several variables, such as the type and concentration of cyclodextrin, the concentration of buffer electrolyte, and the percentage of organic

modifier, are varied simultaneously to find initial separation conditions rapidly. The resulting initial separation conditions can be optimized in further steps to be more reproducible. We discuss the results of the approach when applied on a number of selected compds. that are recently in development at Johnson & Johnson - Pharmaceutical Research and Development. Parameters, such as quality of the separation and anal. time, are evaluated to determine initial separation conditions for each compound

IT 452318-73-9
RL: ANT (Analyte); ANST (Analytical study)
(screening strategy for development of enantiomeric separation methods in capillary electrophoresis)

RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:362586 CAPLUS
DOCUMENT NUMBER: 141:123602
TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety
AUTHOR(S): Pastor, Joaquin; Alcazar, Jesus; Alvarez, Rosa M.; Andres, J. Ignacio; Cid, Jose M.; De Lucas, Ana I.; Diaz, Adolfo; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Lafuente, Celia; Martinez, Sonia; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2917-2922
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:123602

AB The synthesis of a series of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, as novel dual 5-HT reuptake inhibitors and α2-adrenoceptor antagonists is reported.

IT 452313-36-9P 452313-85-8P 452316-95-9P
452316-97-1P 452318-26-2P 452318-71-7P
452318-73-9P 452318-77-3P 452318-83-1P
452318-87-5P 452318-93-3P 452319-01-6P
452319-03-8P 452319-07-2P 452319-09-4P
452320-98-8P 452321-14-1P 452321-21-0P
452321-29-8P 452321-31-2P 722545-47-3P
722545-48-4P 722545-55-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α2-adrenoceptor antagonists)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-85-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-95-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-97-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-07-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-48-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-55-3 CAPLUS
CN Phenol, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452321-75-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and

α2-adrenoceptor antagonists)
RN 452321-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452321-85-6P 452321-97-0P 452321-99-2P
722545-56-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α2-adrenoceptor antagonists)
RN 452321-85-6 CAPLUS
CN 2-Propanone, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-97-0 CAPLUS
CN 1,2-Propanediol, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-99-2 CAPLUS
CN 1-Piperazineacetaldehyde, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 722545-56-4 CAPLUS
CN Phosphonic acid, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-2-oxoethyl]-, diethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 722545-57-5P 722545-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α2-adrenoceptor antagonists)
RN 722545-57-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-

3-phenyl-2-pentenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-58-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3,3-diphenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182890 CAPLUS
DOCUMENT NUMBER: 140:217631
TITLE: Preparation of fused heterocyclic isoxazoline derivatives as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bartolome-Nebreda, Jose Manuel; Fernandez-Gadea, Francisco Javier; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018483	A1	20040304	WO 2003-EP50377	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494557	A1	20040304	CA 2003-2494557	20030813
AU 2003262573	A1	20040311	AU 2003-262573	20030813
EP 1554286	A1	20050720	EP 2003-792431	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675224	A	20050928	CN 2003-819462	20030813
JP 2005538144	T	20051215	JP 2004-530272	20030813
US 2006116378	A1	20060601	US 2005-524123	20050210
PRIORITY APPLN. INFO.:			EP 2002-78373 A	20020815
			WO 2003-EP50377 W	20030813

OTHER SOURCE(S): MARPAT 140:217631
GI



II

AB The invention concerns fused heterocyclic isoxazoline derivs. of formula I [X = CH2, (substituted) NH, S, O; Y = (substituted) heterocyclic ring; Z = (substituted) piperazine, piperidinemethylamine, etc.; R = alkylene-aromatic ring, etc.; m = 1-4], the pharmaceutically acceptable salts thereof, the stereochem. isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivs. fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety, as well as processes for their preparation, pharmaceutical compns. comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia. The compds. have been shown to have selective serotonin (5-HT) reuptake inhibitor activity as well as α2-adrenoceptor antagonist activity. Thus, II was prepared, and had pIC50 if 8.4 in 5-HT transporter binding

experiment
IT 666233-93-8P 666233-95-0P 666233-96-1P
666233-98-3P 666234-00-0P 666234-02-2P
666234-03-3P 666234-04-4P 666234-05-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)
RN 666233-93-8 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[2,3-c]pyridine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 666233-92-7
CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 666233-95-0 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[2,3-c]pyridine, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 666233-94-9
CMF C25 H26 N4 O2

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 666233-96-1 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[2,3-c]pyridine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-98-3 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[2,3-c]pyridine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 666233-97-2
CMF C24 H27 F N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 666234-00-0 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[2,3-b]pyridine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 666233-99-4
CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 666234-02-2 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[3,2-b]pyridine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 666234-01-1
CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 666234-03-3 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[3,2-b]pyridine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666234-04-4 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[3,2-b]pyridine, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666234-05-5 CAPLUS
CN 3H-Isoxazolo[3',4':4,5]pyrano[3,2-b]pyridine, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182889 CAPLUS
DOCUMENT NUMBER: 140:235700
TITLE: Preparation of chromenoisoxazole derivatives and their use as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Matesanz-Ballesteros, Maria Encarnacion; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018482	A2	20040304	WO 2003-EP9532	20030819
WO 2004018482	A3	20040401		
WO 2004018482	A8	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2495058	A1	20040304	CA 2003-2495058 20030819
AU 2003271567	A1	20040311	AU 2003-271567 20030819
EP 1532155	A2	20050525	EP 2003-753363 20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1675223	A	20050928	CN 2003-819862 20030819
JP 2005538143	T	20051215	JP 2004-530256 20030819
US 2006122167	A1	20060608	US 2005-524989 20050218
PRIORITY APPLN. INFO.:			EP 2002-78844 A 20020821
			WO 2003-EP9532 W 20030819

OTHER SOURCE(S): MARPAT 140:235700
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = CH2, NR7, S or O; R7 = H, alkyl, (un)substituted-aryl, -arylalkyl; R1, R2, R14, R15 = independently H, halo, OH, alkyloxy, CN, etc.; m = 1-4; R3 = (un)substituted aromatic homocyclic or heterocyclic ring; R8 = independently OH, amino, nitro, CN, halo, or alkyl; n = 0-5; R9 = H, alkyl, or formyl], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine, in particular for the treatment of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders is disclosed. Thus, e.g., II, was prepared by substitution of 6-bromo-7,8-dimethoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole (preparation given) with N-methylpiperazine. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at least at the hu2A site (but often at the hu2B and hu2C sites) and simultaneously at the 5-HT transporter site of more than 50 % (pIC50) at a test concentration ranging between 10-6 M and 10-9 M in a concentration-dependent manner. The invention also relates to novel combination of isoxazoline derivs. according to the invention with one or more other compds. selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs to improve efficacy and/or onset of action.

IT 667454-35-5P 667454-39-9P 667454-52-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 667454-35-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 6-bromo-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-39-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-6-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-52-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-6-iodo-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 667454-36-6P 667454-37-7P 667454-38-8P
667454-40-2P 667454-41-3P 667454-42-4P

667454-43-5P 667454-44-6P 667454-45-7P
667454-46-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 667454-36-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 6-(4-bromo-1-piperazinyl)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-37-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-6-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-38-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-6-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-40-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-41-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-N-4-pyridinyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-42-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-9-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 667454-43-5 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-44-6 CAPLUS
CN Acetic acid, methoxy-, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 667454-45-7 CAPLUS
CN Acetic acid, methoxy-, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 667454-46-8 CAPLUS
CN Carbamic acid, ethyl-, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-9-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:162696 CAPLUS
DOCUMENT NUMBER: 140:217662
TITLE: Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.
INVENTOR(S): Andres-gil, Jose Ignacio; Bartolome-nebreda, Jose Manuel; Alvarez-escobar, Rosa Maria; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016621	A1	20040226	WO 2003-EP50374	20030812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2494235	A1	20040226	CA 2003-2494235	20030812
AU 2003262571	A1	20040303	AU 2003-262571	20030812
EP 1537124	A1	20050608	EP 2003-787817	20030812
EP 1537124	B1	20070801		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1675222	A	20050928	CN 2003-819483	20030812
JP 2005537304	T	20051208	JP 2004-528523	20030812
AT 368669	T	20070815	AT 2003-787817	20030812
US 2005256119	A1	20051117	US 2005-524197	20050210
PRIORITY APPLN. INFO.:			EP 2002-78322 A	20020812
			WO 2003-EP50374 W	20030812

OTHER SOURCE(S): MARPAT 140:217662
GI



I



II

AB Title compds. [I; X = CH2, NR7, S, O; R7 = H, alkyl aryl, aralkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl; R1, R2 = H, halo, OH, OSO2H, OSO2Me, alkoxy, alkyl, aryl, heterocyclyl, etc.; R1R2 = (CH2)4, CH:CHCH2CH2, CH:CHCH:CH, etc.; Pir = (substituted) piperazinyl, aminomethylpiperidinyl; m = 1-4; R3 = (substituted) (unsatd.) alkylaryl, alkylheteroaryl; with provisos], were prepared Thus, title compound (II) (preparation via intramol. nitrile oxide cycloaddn. given) bound to human platelet 5-HT transporter protein with pIC50 = 7.7.

IT 452320-31-9P 663933-45-7P, 8-Methyl-3-[4-(3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-46-8P, 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-47-9P, [8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]methanol 663933-48-0P, 7-Methoxymethyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-49-1P 663933-50-4P 663933-51-5P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenoxymethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-52-6P 663933-53-7P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-3H-

chromeno[4,3-c]isoxazole 663933-54-8P 663933-55-9P 663933-56-0P, 3-[4-(2-Methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carbonitrile 663933-57-1P 663933-58-2P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carboxylic acid ethylamide 663933-59-3P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-60-6P, 1-[5-[8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]thiophen-2-yl]ethanone 663933-61-7P 663933-62-8P 663933-63-9P 663933-65-1P 663933-66-2P 663933-68-4P 663933-69-5P 663933-70-8P 663933-71-9P 663933-72-0P 663933-74-2P 663933-76-4P 663933-77-5P 663933-78-6P 663933-79-7P 663933-80-0P 663933-81-1P 663933-89-9P 663933-90-2P 663933-91-3P 663933-92-4P 663933-93-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)

RN 452320-31-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-45-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-(3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-46-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-47-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-48-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-49-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[(2-

methoxyethoxy]methoxy]methyl]-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 663933-50-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 663933-51-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-7-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 663933-52-6 CAPLUS
CN Ethanol, 2-[[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)



RN 663933-53-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 663933-54-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, oxime (9CI) (CA INDEX NAME)



RN 663933-55-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 663933-56-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-57-1 CAPLUS
CN Acetamide, N-[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-58-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide, N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 663933-59-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-7-phenyl- (9CI) (CA INDEX NAME)



RN 663933-60-6 CAPLUS
CN Ethanone, 1-[5-[3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 663933-61-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-62-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-63-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-,

dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 663933-65-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[(2-methoxyethoxy)methoxy]methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-64-0
CMF C31 H41 N3 O6

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-66-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-68-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(phenoxymethyl)-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-67-3
CMF C33 H37 N3 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-69-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-70-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, oxime, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.



RN 663933-71-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-72-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-74-2 CAPLUS
CN Acetamide, N-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]-, rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-73-1
CMF C28 H34 N4 O3

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-76-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide, N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 663933-75-3
CMF C29 H36 N4 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 663933-77-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-78-6 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 663933-79-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3S,3aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 663933-80-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 663933-81-1 CAPLUS
CN Ethanone, 1-[4-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-89-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-90-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 663933-91-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-92-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine, N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-93-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-[(4-methyl-1-piperidinyl)methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

IT 663933-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)
RN 663933-88-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:892834 CAPLUS
DOCUMENT NUMBER: 139:365764
TITLE: Diblock copolymers for use in pharmaceutical dosage

forms
INVENTOR(S): Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna; Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093344	A1	20031113	WO 2003-EP4368	20030424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483282	A1	20031113	CA 2003-2483282	20030424
AU 2003222310	A1	20031117	AU 2003-222310	20030424
EP 1504047	A1	20050209	EP 2003-717321	20030424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009688	A	20050222	BR 2003-9688	20030424
NZ 536294	A	20050527	NZ 2003-536294	20030424
CN 1649932	A	20050803	CN 2003-809579	20030424
JP 2005524730	T	20050818	JP 2004-501483	20030424
MX 2004PA10778	A	20050307	MX 2004-PA10778	20041029
ZA 2004008854	A	20051102	ZA 2004-8854	20041102
NO 2004005283	A	20050107	NO 2004-5283	20041202
US 2006034797	A1	20060216	US 2005-522456	20050121
PRIORITY APPLN. INFO.:			US 2002-377901P P	20020503
			WO 2003-EP4368 W	20030424

AB In a diblock copolymer of formula A-B, polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer and polymer block B represents a polymer comprising monomers selected from L-lactic acid, D-lactic acid, D,L-lactic acid, glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ω-lactone, 1,5-dioxepan-2-one or mixts. thereof characterized in that the diblock copolymer is liquid at a temperature below 50°. A polymer was prepared from ε-caprolactone, trimethylene carbonate, and polyethylene glycol monomethyl ether initiator.

IT 452314-01-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diblock copolymers for use in pharmaceutical dosage forms)
RN 452314-01-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796712 CAPLUS
DOCUMENT NUMBER: 139:307799
TITLE: Preparation of isoxazoline derivatives as antidepressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bakker, Margaretha Henrica Maria; De Lucas Olivares, Ana Isabel
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082878	A1	20031009	WO 2003-EP3245	20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480113	A1	20031009	CA 2003-2480113	20030327
AU 2003219111	A1	20031013	AU 2003-219111	20030327
BR 2003008309	A	20041228	BR 2003-8309	20030327
EP 1492796	A1	20050105	EP 2003-714897	20030327
EP 1492796	B1	20070905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642960	A	20050720	CN 2003-807419	20030327
JP 2005522469	T	20050728	JP 2003-580343	20030327
NZ 536109	A	20060630	NZ 2003-536109	20030327
MX 2004PA08626	A	20041206	MX 2004-PA8626	20040906

IN 2004DN02809	A	20050401	IN 2004-DN2809		20040921
ZA 2004007904	A	20051020	ZA 2004-7904		20040930
US 2005222125	A1	20051006	US 2004-510220		20041001
US 7265103	B2	20070904			
NO 2004004645	A	20041027	NO 2004-4645		20041027
PRIORITY APPLN. INFO.:			EP 2002-76239	A	20020402
			WO 2003-EP3245	W	20030327

OTHER SOURCE(S): MARPAT 139:307799

GI



I



II

AB The title isoxazoline derivs. having a piperazinyl subunit with general formula of I [wherein X = CH2, S, O, or (un)substituted NH; R1 and R2 = independently H, OH, CN, halo, OSO2H, OSO2Me, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, tetrahydrofuranyloxy, alkylthio, (alkoxy)alkylcarboxy, pyridylcarboxy, alkylcarboxyalkoxy, alkoxycarboxy, alkenyloxy, alkenylcarboxy, alkylaminoalkoxy, dialkylaminoalkoxy, or (un)substituted NH2, with provisos; m = 1-4; A = (un)substituted piperazinyl, piperidinyl, or amino; R3 = (un)substituted aromatic (hetero)cyclyl] and pharmaceutically acceptable salts, stereoisomers, N-oxides, or prodrugs thereof are prepared as antidepressants for the treatment of depression, anxiety, and/or body weight disorders (no data). For example, the compound II •2HCl was prepared in a multi-step synthesis in moderate yield. II showed pIC50 of 8.9, 9.0, and 8.2 against human hu2A, hu2C, and 5-HT transporter receptor sites, resp.

IT 612074-52-9P 612074-55-2P 612074-58-5P
612074-59-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-52-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-55-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-58-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-59-6 CAPLUS

CN 1,2-Ethanediamine, N'-[(3R,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 612074-51-8P 612074-53-0P 612074-54-1P
612074-56-3P 612074-57-4P 612074-60-9P
612074-61-0P 612074-67-6P 612074-68-7P
612074-69-8P 612074-70-1P 612074-71-2P
612074-72-3P 612074-73-4P 612074-74-5P
612074-75-6P 612074-76-7P 612074-77-8P
612074-78-9P 612074-79-0P 612074-80-3P
612074-81-4P 612074-82-5P 612074-83-6P
612074-84-7P 612074-85-8P 612074-86-9P
612074-87-0P 612074-88-1P 612074-89-2P
612074-90-5P 612074-91-6P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-96-1P 612074-97-2P 612074-98-3P
612074-99-4P 612075-00-0P 612075-01-1P
612075-02-2P 612075-03-3P 612075-04-4P
612075-05-5P 612075-06-6P 612075-07-7P
612075-08-8P 612075-09-9P 612075-10-2P
612075-11-3P 612075-12-4P 612075-13-5P
612075-14-6P 612075-15-7P 612075-16-8P
612075-17-9P 612075-18-0P 612075-19-1P
612075-20-4P 612075-21-5P 612075-22-6P
612075-23-7P 612075-24-8P 612075-25-9P
612075-26-0P 612075-27-1P 612075-28-2P
612075-29-3P 612075-30-6P 612075-31-7P
612075-32-8P 612075-33-9P 612075-34-0P
612075-35-1P 612075-40-8P 612075-42-0P
612075-43-1P 612075-44-2P 612075-45-3P
612075-46-4P 612075-47-5P 612075-48-6P
612075-49-7P 612075-50-0P 612075-51-1P
612075-52-2P 612075-53-3P 612075-54-4P
612075-55-5P 612075-56-6P 612075-57-7P
612075-58-8P 612075-59-9P 612075-60-2P
612075-61-3P 612075-62-4P 612075-63-5P
612075-64-6P 612075-65-7P 612075-66-8P
612075-67-9P 612075-68-0P 612075-69-1P
612075-70-4P 612075-71-5P 612075-72-6P
612075-73-7P 612075-74-8P 612075-75-9P
612075-76-0P 612075-77-1P 612075-78-2P
612075-79-3P 612075-80-6P 612075-81-7P
612075-82-8P 612075-83-9P 612075-84-0P
612075-85-1P 612075-86-2P 612075-87-3P
612075-88-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-51-8 CAPLUS

CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



•2 HCl

RN 612074-53-0 CAPLUS

CN Benzenesulfonamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612074-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-(4-morpholinyl)-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-56-3 CAPLUS
CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-57-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-dimethoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-60-9 CAPLUS
CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-61-0 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-67-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-methyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-68-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-69-8 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● HCl

RN 612074-70-1 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● HCl

PAGE 1-B

NHMe

RN 612074-71-2 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N'-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

NHMe

RN 612074-72-3 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 HCl

PAGE 1-B

NMe_2

RN 612074-73-4 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● HCl

PAGE 1-B

NMe_2

RN 612074-74-5 CAPLUS
CN 1,2-Ethanediamine, N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

NMe_2

RN 612074-75-6 CAPLUS
CN 1,2-Ethanediamine, N,N-diethyl-N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● HCl

PAGE 1-B

NEt_2

RN 612074-76-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-78-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-79-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-80-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-[2-(4-morpholinyl)ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-82-5 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-83-6 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-84-7 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-85-8 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-86-9 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-87-0 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-phenyl-,

(3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(4-methoxyphenyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



OMe

RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-94-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-95-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-96-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 612074-97-2 CAPLUS

CN Acetamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-98-3 CAPLUS
CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-99-4 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-00-0 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-01-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-02-2 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-03-3 CAPLUS
CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-04-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 612075-05-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 612075-06-6 CAPLUS
CN Carbamic acid, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-08-8 CAPLUS
CN Imidodicarbonic diamide, N,N'-diethyl-2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-09-9 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-10-2 CAPLUS
CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS
CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-14-6 CAPLUS
CN Methanesulfonamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-

(methylsulfonyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-15-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-16-8 CAPLUS
CN 1-Piperazinecarboximidamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-(phenylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-17-9 CAPLUS
CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-pyrrolidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-19-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-20-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

OEt

RN 612075-21-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-22-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-23-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-24-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-25-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-26-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-phenyl-1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-27-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-[4-(phenylmethyl)-1-piperazinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Ph

RN 612075-28-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-29-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-30-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-31-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-32-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-33-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-34-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 612075-35-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-40-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-amine, 3a,4-dihydro-N-(4-methoxyphenyl)-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-42-0 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-43-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-1-pyrrolidinyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-44-2 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-45-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(1-ethylpropyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-46-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylpropyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-47-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-4-pyridinyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-48-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(2-methyl-1-pyrrolidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-49-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(1-azetidinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-50-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperidinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-51-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylbutyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-52-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-

methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-53-3 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-54-4 CAPLUS
CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-55-5 CAPLUS
CN Cyclobutanecarboxylic acid, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-56-6 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-57-7 CAPLUS
CN 1,2-Ethanediamine, N'-(1,2-dimethylpropyl)-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-58-8 CAPLUS
CN 1,2-Ethanediamine, N'-cyclobutyl-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-59-9 CAPLUS
CN 2-Butenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

—Me

RN 612075-60-2 CAPLUS
CN Pentanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-61-3 CAPLUS
CN Butanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-62-4 CAPLUS
CN Cyclobutanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-63-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylpropyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-64-6 CAPLUS
CN Butanoic acid, 3,3-dimethyl-, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-65-7 CAPLUS
CN 1,2-Ethanediamine, N'-(cyclopropylmethyl)-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-66-8 CAPLUS
CN 2-Propanol, 1-[[2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-67-9 CAPLUS
CN 1,2-Ethanediamine, N'-(1,1-dimethylpropyl)-N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-

[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-68-0 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N'-dimethyl-N'-2-propenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-69-1 CAPLUS
CN 1,2-Ethanediamine, N-(1,1-dimethylethyl)-N'-[(3R,3aS)-3-[[4-[(2E)-3-(4-

fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N'-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-70-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-[2-(1-azetidinyl)ethyl]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-methyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 612075-71-5 CAPLUS
CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-72-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-7-(hexahydro-1H-azepin-1-yl)-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-73-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(2-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

RN 612075-74-8 CAPLUS
CN Carbamic acid, (1-methylpropyl)-, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 612075-75-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(1-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-76-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-77-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-78-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylpropyl)-,

(3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-79-3 CAPLUS
CN 2-Propanol, 1-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-N-pentyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-81-7 CAPLUS

CN 1-Propanol, 2-[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-82-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,6-dihydro-1(2H)-pyridinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperazinyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-84-0 CAPLUS
CN Urea, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-85-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-86-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-87-3 CAPLUS
CN 1,2-Ethanediamine, N-[(3S,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[[(1R,2S)-2-phenylcyclopropyl]methyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 612075-88-4 CAPLUS
CN 1,2-Ethanediamine, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N,N',N'-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of isoxazoline derivs. as antidepressants)
RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-78-7 612075-96-4 612075-97-5
612075-98-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoxazoline derivs. as antidepressants)
RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-96-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-97-5 CAPLUS
CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-98-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:535065 CAPLUS
DOCUMENT NUMBER: 139:292184

TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities: a novel series of potential antidepressants
AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Martinez, Sonia; Nieto, Carmen; Pastor, Joaquin; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Jarama s/n, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(16), 2719-2725
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:292184

AB The synthesis of a series of novel 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as novel dual 5-HT re-uptake inhibitors and α2-adrenoceptor antagonists is described. Their affinity at the three different human α2-adrenoceptor subtypes and the 5-HT transporter site is reported. The in vivo activity of the compds. was measured in two different assays: (1) inhibition of pCA-induced excitation, which evaluates the ability to block the central 5-HT transporter, and (2) inhibition of xylazine-induced loss of righting, which evaluates the ability to block central α2-adrenoceptors. Compds. thus prepared included (3R,3aS)-rel-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole, (3R,3aS)-rel-(-)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole, (3R,3aS)-rel-(+)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole and derivs. thereof.

IT 452313-36-9P 452313-43-8P 452313-54-1P
452313-56-3P 452313-77-8P 452314-18-0P
452316-09-5P 452316-15-3P 452316-21-1P
452316-33-5P 452316-36-8P 452316-66-4P
452316-84-6P 452318-20-6P 452318-24-0P
452318-26-2P 452318-93-3P 452318-95-5P
452318-97-7P 452319-25-4P 452319-35-6P
452320-01-3P 608146-10-7P 608146-11-8P
608146-12-9P 608146-13-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as 5-HT uptake inhibitors and α2-adrenoceptor antagonists (potential antidepressants))

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-43-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-09-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.



RN 452316-15-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-21-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-33-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-66-4 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-84-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl)methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 608146-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 608146-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 608146-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 608146-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452321-75-4P 452321-82-3P 452321-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as

5-HT uptake inhibitors and α2-adrenoceptor antagonists (potential antidepressants))
RN 452321-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-82-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-89-0 CAPLUS
CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, bromide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:658130 CAPLUS
DOCUMENT NUMBER: 137:201298
TITLE: Preparation of substituted isoxazolines as anti-depressants
INVENTOR(S): Andres-Gil, Jose Ignacio; Fernandez-Gadea, Francisco Javier; Alcazar-Vaca, Manuel Jesus; Cid-Nunez, Jose Maria; Pastor-Fernandez, Joaquin; Megens, Antonius Adrianus Hendrikus Petrus; Heylen, Godelieve Irma Christine Maria; Langlois, Xavier Jean Michel; Bakker, Margaretha Henrica Maria; Steckler, Thomas Horst Wolfgang
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066484	A1	20020829	WO 2002-EP1567	20020213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437505	A1	20020829	CA 2002-2437505	20020213
AU 2002244717	A1	20020904	AU 2002-244717	20020213
AU 2002244717	B2	20070719		
EP 1368358	A1	20031210	EP 2002-712909	20020213
EP 1368358	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

EE 200300398	A	20031215	EE 2003-398		20020213
HU 200303270	A2	20040128	HU 2003-3270		20020213
HU 200303270	A3	20070328			
CN 1492871	A	20040428	CN 2002-805243		20020213
NZ 526741	A	20040430	NZ 2002-526741		20020213
BR 2002007433	A	20040601	BR 2002-7433		20020213
JP 2004518748	T	20040624	JP 2002-565998		20020213
JP 3953424	B2	20070808			
AT 337322	T	20060915	AT 2002-712909		20020213
ES 2271230	T3	20070416	ES 2002-2712909		20020213
TW 257392	B	20060701	TW 2002-91102853		20020220
IN 2003DN00968	A	20070525	IN 2003-DN968		20030624
BG 107984	A	20040930	BG 2003-107984		20030708
MX 2003PA07432	A	20031118	MX 2003-PA7432		20030819
NO 2003003700	A	20031021	NO 2003-3700		20030820
ZA 2003006487	A	20041122	ZA 2003-6487		20030820
US 2004122037	A1	20040624	US 2003-468555		20030821
US 7169786	B2	20070130			
PRIORITY APPLN. INFO.:			EP 2001-200611	A	20010221
			EP 2001-201264	A	20010405
			WO 2002-EP1567	W	20020213

OTHER SOURCE(S): MARPAT 137:201298
GI



I



II



III

AB Title compds. I [wherein X = CH2, NR7, S or O; R7 = H, (un)substituted alkyl, Ph, Ph alkyl, etc.; R1 and R2 independently = H, OH, CN, halo, OSO2H, (un)substituted Ph, phenylalkyl, alkoxy, etc.; or R1 and R2 may be taken together to form a bivalent radical selected from -CH2CH2O-, -OCH2CH2-, -OCH2O-, -CH2OCH2- and -OCH2CH2O-; m = 1-4; Y = (un)substituted piperidyl or piperazyl radical and R3 represents an (un)substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Y radical and which may contain one or more heteroatoms selected from the group of O, N and S], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine for treating anxiety disorders and disorders of body weight are disclosed. Thus, II was prepared in 60% yield by reaction of III with N-(3-phenyl-2-propenyl)-piperazine. III was prepared by substitution of Me 4-bromo-2-butenoate with 2-hydroxy-4,5-dimethoxybenzaldehyde with subsequent condensation with hydroxylamine, cyclization, reduction and sulfonation with methanesulfonyl chloride. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at the hα2A site (but often also at the hα2B and hα2C sites) and simultaneously at the 5-HT transporter site of more than 50% (pIC50) at a test concentration ranging between 10-6 M and 10-9 M in a concentration dependent manner. The invention also relates to novel combination of substituted isoxazolines derivs. having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

IT 452321-75-4P 452321-82-3P 452321-85-6P
452321-87-8P 452321-89-0P 452321-91-4P
452321-93-6P 452321-95-8P 452321-97-0P
452321-99-2P 452322-19-9P 452322-21-3P
452322-23-5P 452322-29-1P 452322-30-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452321-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-82-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-85-6 CAPLUS
CN 2-Propanone, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-87-8 CAPLUS
CN Piperazine, 1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-[(3,4-dihydro-2-naphthalenyl)carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-89-0 CAPLUS
CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, bromide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

RN 452321-91-4 CAPLUS
CN Piperazine, 1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-(3-iodo-2-methyl-1-oxo-2-propenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452321-93-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-iodo-2-methyl-2-propenyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452321-95-8 CAPLUS
CN 1-Piperazineethanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]- α-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-97-0 CAPLUS
CN 1,2-Propanediol, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-99-2 CAPLUS
CN 1-Piperazineacetaldehyde, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-19-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-21-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-23-5 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-29-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]amino]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452322-30-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-(4-piperidinylmethyl)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452323-46-5D, resin bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452323-46-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(diphenylphosphino)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452313-32-5P 452313-68-7P 452313-71-2P
452313-80-3P 452313-82-5P 452316-78-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452313-32-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452313-68-7 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-80-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



●2 HCl

RN 452313-82-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



●2 HCl

RN 452316-78-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

IT 452313-59-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
RN 452313-59-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 452313-36-9P 452313-40-5P 452313-43-8P
452313-46-1P 452313-50-7P 452313-54-1P
452313-56-3P 452313-61-0P 452313-65-4P
452313-74-5P 452313-77-8P 452313-85-8P
452313-88-1P 452313-91-6P 452313-93-8P
452313-98-3P 452314-01-1P 452314-05-5P
452314-08-8P 452314-11-3P 452314-14-6P
452314-16-8P 452314-18-0P 452314-20-4P
452314-23-7P 452314-26-0P 452314-29-3P
452314-31-7P 452314-34-0P 452314-37-3P
452314-40-8P 452314-43-1P 452314-46-4P
452314-49-7P 452314-52-2P 452314-55-5P
452314-57-7P 452314-60-2P 452314-62-4P
452314-65-7P 452314-68-0P 452314-71-5P
452314-74-8P 452314-77-1P 452314-80-6P
452314-83-9P 452314-86-2P 452314-89-5P
452314-92-0P 452314-95-3P 452314-98-6P
452315-01-4P 452315-04-7P 452315-07-0P
452315-10-5P 452315-13-8P 452315-16-1P
452315-19-4P 452315-22-9P 452315-24-1P
452315-27-4P 452315-30-9P 452315-33-2P
452315-36-5P 452315-38-7P 452315-40-1P
452315-42-3P 452315-44-5P 452315-46-7P
452315-48-9P 452315-51-4P 452315-52-5P
452315-55-8P 452315-58-1P 452315-61-6P
452315-63-8P 452315-66-1P 452315-70-7P
452315-73-0P 452315-76-3P 452315-79-6P
452315-82-1P 452315-85-4P 452315-87-6P
452315-90-1P 452315-92-3P 452315-94-5P
452315-97-8P 452316-00-6P 452316-03-9P
452316-06-2P 452316-09-5P 452316-12-0P
452316-15-3P 452316-18-6P 452316-21-1P
452316-24-4P 452316-27-7P 452316-30-2P
452316-33-5P 452316-36-8P 452316-39-1P
452316-42-6P 452316-45-9P 452316-48-2P
452316-51-7P 452316-53-9P 452316-55-1P
452316-58-4P 452316-64-2P 452316-66-4P
452316-69-7P 452316-72-2P 452316-75-5P
452316-81-3P 452316-84-6P 452316-87-9P
452316-89-1P 452316-91-5P 452316-93-7P
452316-95-9P 452316-97-1P 452316-99-3P
452317-02-1P 452317-04-3P 452317-06-5P
452317-08-7P 452317-10-1P 452317-12-3P
452317-14-5P 452317-16-7P 452317-18-9P
452317-20-3P 452317-22-5P 452317-24-7P
452317-26-9P 452317-28-1P 452317-30-5P

452317-32-7P 452317-34-9P 452317-36-1P
452317-38-3P 452317-40-7P 452317-42-9P
452317-44-1P 452317-46-3P 452317-48-5P
452317-50-9P 452317-52-1P 452317-54-3P
452317-56-5P 452317-58-7P 452317-60-1P
452317-64-5P 452317-67-8P 452317-69-0P
452317-71-4P 452317-73-6P 452317-76-9P
452317-79-2P 452317-82-7P 452317-84-9P
452317-86-1P 452317-89-4P 452317-92-9P
452317-94-1P 452317-96-3P 452317-99-6P
452318-02-4P 452318-04-6P 452318-07-9P
452318-09-1P 452318-11-5P 452318-13-7P
452318-15-9P 452318-18-2P 452318-20-6P
452318-22-8P 452318-24-0P 452318-27-3P
452318-30-8P 452318-32-0P 452318-34-2P
452318-36-4P 452318-38-6P 452318-41-1P
452319-43-3P 452318-45-5P 452318-47-7P
452318-49-9P 452318-52-4P 452318-54-6P
452318-57-9P 452318-60-4P 452318-63-7P
452318-65-9P 452318-67-1P 452318-69-3P
452318-71-7P 452318-73-9P 452318-75-1P
452318-77-3P 452318-79-5P 452318-81-9P
452318-83-1P 452318-85-3P 452318-87-5P
452318-89-7P 452318-91-1P 452318-93-3P
452318-95-5P 452318-97-7P 452318-99-9P
452319-01-6P 452319-03-8P 452319-05-0P
452319-07-2P 452319-09-4P 452319-11-8P
452319-13-0P 452319-15-2P 452319-17-4P
452319-20-9P 452319-22-1P 452319-24-3P
452319-25-4P 452319-27-6P 452319-29-8P
452319-31-2P 452319-33-4P 452319-35-6P
452319-37-8P 452319-39-0P 452319-41-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452313-36-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-40-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-43-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-46-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-50-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-54-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-61-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-74-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-85-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methylphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dihydro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452313-98-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-05-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-butenyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452314-08-8 CAPLUS
CN 1-Piperazineethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]- α-methyl-N-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-11-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-14-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452314-16-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-20-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-23-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-26-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-29-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-

(1,1,2,2-tetrafluoroethyl)phenyl]methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-31-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-34-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-37-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-40-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-43-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452314-46-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-49-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-nitrophenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-52-2 CAPLUS
CN Benzenamine, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 452314-55-5 CAPLUS
CN Acetamide, N-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX

NAME)



RN 452314-57-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-ethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-60-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-62-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-65-7 CAPLUS
CN 1-Propanamine, 3-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 452314-68-0 CAPLUS
CN Benzoic acid, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 452314-71-5 CAPLUS
CN Benzonitrile, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-74-8 CAPLUS
CN Benzonitrile, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452314-77-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452314-86-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-89-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-92-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-95-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452314-98-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-01-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thiazolylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-04-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-4-thiazolyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-07-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.



RN 452315-10-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-13-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-16-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-furanylmethyl)-1-

piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-19-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-22-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-24-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-27-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-30-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-33-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[(4-(3-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-36-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3R,5S)-3,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-38-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,5S)-2,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-40-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[3-methyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-42-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452315-44-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 452315-46-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-48-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-51-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-52-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(7-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-55-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-58-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methyl-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-61-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-63-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-66-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-70-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-chloro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-73-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(1-bromo-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-76-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-nitro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-79-6 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-82-1 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-85-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-87-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-90-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7,8-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-92-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-8-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-94-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452315-97-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-00-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-03-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-06-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-09-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-12-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-quinolinylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452316-15-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-18-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-21-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-24-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-27-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-30-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-33-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-39-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-42-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452316-45-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-48-2 CAPLUS
CN 1H-Inden-1-one, 5-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethoxy]-2,3-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-51-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-[(2,3-dihydro-5-benzofuranyl)oxy]ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-53-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-55-1 CAPLUS
CN 3(2H)-Benzofuranone, 6-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methylethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-58-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[[(2R)-6-fluoro-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl]methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-64-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-66-4 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-69-7 CAPLUS
CN 1-Piperazinepropanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]- α-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452316-72-2 CAPLUS
CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, oxime, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-75-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-81-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propenyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-84-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-87-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-89-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-91-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452316-93-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-phenoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-95-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-97-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452316-99-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-02-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452317-04-3 CAPLUS
CN Naphth[1,2-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-06-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-08-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-10-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-chlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-12-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-14-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-16-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-18-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-20-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[3-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-22-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[4-(trifluoromethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-24-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(1,1,2,2-tetrafluoroethyl)phenyl]-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-26-9 CAPLUS
CN Benzoic acid, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-28-1 CAPLUS
CN Benzoic acid, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-30-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-32-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-34-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-methylphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-36-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-phenoxyphenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-38-3 CAPLUS
CN Benzonitrile, 2-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-40-7 CAPLUS
CN Benzonitrile, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-42-9 CAPLUS
CN Benzonitrile, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-44-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[1,1'-biphenyl]-2-yl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-46-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,4-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-48-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,4-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-50-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-52-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-54-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,5-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-56-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,5-difluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-58-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-dichlorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-60-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452317-64-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-6-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-67-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-1H-inden-5-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-69-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-

yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-71-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9H-fluoren-2-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-73-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-dibenzofuranyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-76-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(1,3-benzodioxol-5-yl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-79-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-5-benzofuranyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-82-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4,5-dimethoxy-2-nitrophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-84-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-86-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-89-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI)

(CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-92-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromo-2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-94-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(5-bromo-2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-96-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-furanyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-99-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-02-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-04-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[5-(4-chlorophenyl)-2-furanyl]-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452318-11-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-quinolinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-13-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-quinolinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-15-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9-anthracenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 452318-18-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-1-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI)

(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-22-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452318-24-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 452318-26-2
CMF C27 H33 N3 O4

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 452318-30-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,5S)-2,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-32-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3R,5S)-3,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2R,6S)-2,6-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-36-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-38-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 452318-41-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2,3-diphenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)



RN 452318-43-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-[1,1'-biphenyl]-4-yl-3-phenyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-45-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-(2-naphthalenyl)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-47-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(phenylmethylene)butyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-49-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-(phenylmethylene)heptyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-52-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-bromo-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-54-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-chloro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-57-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-60-4 CAPLUS
CN 1-Piperazinepropanenitrile, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]- α-(phenylmethylene)-, (αZ)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-63-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-65-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-4-yl-2-methyl-2-propenyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-67-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-79-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chloro-6-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-81-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-85-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-89-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-methyl-3-(1-naphthalenyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-91-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2H-1-benzopyran-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-99-9 CAPLUS
CN Phenol, 3-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-propenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-05-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-dimethyl-3-thienyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-07-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-methyl-4-thiazolyl)-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1-cyclopenten-1-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-15-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propynyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-17-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-20-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452319-22-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-4-(2-fluorophenyl)-2-methyl-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-24-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E,4E)-5-phenyl-2,4-pentadienyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-27-6 CAPLUS
CN Benzoic acid, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI)

(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-33-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452319-37-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-39-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-43-6P 452319-45-8P 452319-47-0P
452319-49-2P 452319-51-6P 452319-53-8P
452319-55-0P 452319-57-2P 452319-59-4P
452319-61-8P 452319-63-0P 452319-65-2P
452319-67-4P 452319-69-6P 452319-71-0P
452319-73-2P 452319-75-4P 452319-77-6P
452319-78-7P 452319-80-1P 452319-81-2P
452319-83-4P 452319-85-6P 452319-87-8P
452319-89-0P 452319-91-4P 452319-93-6P
452319-95-8P 452319-97-0P 452319-99-2P
452320-01-3P 452320-03-5P 452320-06-8P
452320-07-9P 452320-09-1P 452320-11-5P
452320-13-7P 452320-15-9P 452320-17-1P
452320-19-3P 452320-21-7P 452320-23-9P
452320-25-1P 452320-27-3P 452320-29-5P
452320-31-9P 452320-34-2P 452320-36-4P
452320-38-6P 452320-40-0P 452320-42-2P
452320-44-4P 452320-46-6P 452320-48-8P
452320-50-2P 452320-52-4P 452320-54-6P
452320-56-8P 452320-58-0P 452320-60-4P
452320-62-6P 452320-64-8P 452320-66-0P
452320-68-2P 452320-70-6P 452320-72-8P
452320-74-0P 452320-76-2P 452320-78-4P
452320-80-8P 452320-82-0P 452320-84-2P
452320-86-4P 452320-88-6P 452320-90-0P
452320-92-2P 452320-94-4P 452320-96-6P
452320-98-8P 452321-00-5P 452321-02-7P
452321-04-9P 452321-06-1P 452321-08-3P
452321-10-7P 452321-12-9P 452321-14-1P
452321-16-3P 452321-19-6P 452321-21-0P
452321-23-2P 452321-25-4P 452321-27-6P
452321-29-8P 452321-31-2P 452321-33-4P
452321-35-6P 452321-37-8P 452321-39-0P
452321-41-4P 452321-43-6P 452321-45-8P
452321-47-0P 452321-55-0P 452321-57-2P
452321-59-4P 452321-61-8P 452934-93-9P
452934-94-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452319-43-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-45-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-47-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-49-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452319-51-6 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-53-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, propanoate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS
CN Acetic acid, methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS
CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-69-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-71-0 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-73-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, hydrogen sulfite (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-75-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-77-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-80-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-81-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(-)- (9CI) (CA

INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-83-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7,8-difluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-85-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-87-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-phenyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-89-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-91-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-93-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452319-95-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-97-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-99-2 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-8-yl]oxy]-, acetate (ester), rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-03-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-06-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-11-5 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-13-7 CAPLUS
CN 3-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-15-9 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-17-1 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-19-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-21-7 CAPLUS
CN Carbonic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-23-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(2-propenyloxy)-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-25-1 CAPLUS
CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452320-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, methanesulfonate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-29-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-31-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 452320-33-1
CMF C27 H33 N3 O3 S

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 452320-36-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-38-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-42-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-44-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(+)-

(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-46-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-48-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propenyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-50-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-56-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(phenylmethyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-58-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-5-(trifluoroacetyl)-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 5-acetyl-3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-68-2 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-72-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-74-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-76-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 452320-78-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-80-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-82-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-84-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(difluoromethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-86-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-7-[(tetrahydro-3-furanyl)oxy]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-88-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-90-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452320-92-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, acetate (ester), (3R,3aS)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-94-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-96-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-00-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-02-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-04-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-06-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-08-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methylphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-16-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-19-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, dihydrochloride, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



●2 HCl

RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-23-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3,4-difluorophenyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-pyridinyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-27-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-pyridinyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-butenyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-33-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-35-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-37-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-butenyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.



RN 452321-43-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-45-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyloxy)ethyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-47-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[2-[4-(2-naphthalenylmethyl)-1-piperazinyl]ethyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-methyl-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-59-4 CAPLUS
CN Formamide, N-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-N-(1-(2-naphthalenylmethyl)-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452321-61-8 CAPLUS
CN 1-Piperazinemethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-N-2-naphthalenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452934-93-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2,3,4a,8a-tetrahydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 452934-94-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-3,4,4a,8a-tetrahydro-4-methyl-2H-1,4-benzoxazin-2-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:260283 CAPLUS
DOCUMENT NUMBER: 132:293757
TITLE: Preparation of novel 4,5-dihydroisoxazole derivatives and their use as pharmaceuticals for T cell-mediated diseases
INVENTOR(S): Freyne, Eddy Jean Edgard; Andres-Gil, Jose Ignacio; Deroose, Frederik Dirk; Petit, Davy Petrus Franciscus Maria; Matesanz-Ballesteros, Maria Encarnacion; Alvarez Escobar, Rosa Maria
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021959	A1	20000420	WO 1999-EP7803	19991007
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2346396	A1	20000420	CA 1999-2346396		19991007
EP 1119568	A1	20010801	EP 1999-953847		19991007
EP 1119568	B1	20040218			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002527438	T	20020827	JP 2000-575865		19991007
AU 763460	B2	20030724	AU 2000-10393		19991007
AT 259803	T	20040315	AT 1999-953847		19991007
ES 2216579	T3	20041016	ES 1999-953847		19991007
US 6583141	B1	20030624	US 2001-807149		20010406
HK 1038565	A1	20040618	HK 2002-100274		20020115
US 2004019059	A1	20040129	US 2003-403543		20030331
PRIORITY APPLN. INFO.:			EP 1998-203394	A	19981009
			WO 1999-EP7803	W	19991007
			US 2001-807149	A3	20010406

OTHER SOURCE(S): MARPAT 132:293757

GI



I



II

AB The invention concerns title compds. I and their N-oxides, pharmaceutically acceptable addition salts, quaternary ammonium salts, and stereochem. isomeric forms [wherein m, n, p = 0 or 1; R1 = (un)substituted pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl; B = amide, ketone, or oxadiazole; D = (un)substituted aryl or heterocyclyl; Q = bond, CO, (un)substituted NH, CONH, CH2, CH(:CH2), C(:NH), SO, SO2, 3-oxobutenyl, pyrazole, isoxazole, or thiazole nucleus; L = (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-6 alkyloxy, or (un)substituted C1-6 alkyl]. Also disclosed is a process for their preparation, compns. comprising them, and their medical use. The compds. show growth inhibitory activity against T cell blasts and keratinocytes in vitro. The compds. are claimed for use in the treatment of prevention of rheumatic, arthritic, and inflammatory diseases, psoriasis, T cell leukemia, transplant rejection,

and graft-vs.-host disease. For instance, base-catalyzed cycloaddn. of N-hydroxy-3-pyridinecarboximidoyl chloride with Me 2-propenoate gave 98% Me 4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxylate, which was amidated with (4-aminophenyl)phenylmethanone to give 58% title compound II. At a concentration of 10-6 M, II gave 81% inhibition of T cell blast formation in human whole blood.

IT 264606-16-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-16-8 CAPLUS

CN Piperidine, 4-(4-fluorobenzoyl)-1-[[(3R,3aR)-3,3a,4,5-tetrahydroisoxazolo[4,3-c]quinolin-3-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:48:58 ON 25 SEP 2007)

FILE 'REGISTRY' ENTERED AT 15:49:08 ON 25 SEP 2007
L1 STRUCTURE UPLOADED
L2 0 S L1 FULL
L3 STRUCTURE UPLOADED
L4 0 S L3 FULL
L5 STRUCTURE UPLOADED
L6 689 S L5 FULL

FILE 'CAPLUS' ENTERED AT 15:56:42 ON 25 SEP 2007
L7 14 S L6 FULL